[{"title":"Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China","googleId":"rgyxI7N8O5gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420363833","googleCitationCount":771,"googleAuthor":"L Xie"},{"title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","googleId":"jbBfhU99zq4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309974","googleCitationCount":427,"googleAuthor":"M Yarchoan"},{"title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"9BFapTr-f0EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31287-6/abstract","googleCitationCount":383,"googleAuthor":"F Cardoso"},{"title":"ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours …","googleId":"hWQqZLH2abIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311627","googleCitationCount":204,"googleAuthor":"N Colombo"},{"title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","googleId":"-rKOmtHlwLEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931110X","googleCitationCount":214,"googleAuthor":"A Daud"},{"title":"Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n= 4532)","googleId":"6VRrWkF6U90J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420397970","googleCitationCount":208,"googleAuthor":"M Rugge"},{"title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","googleId":"BsHjnbvXKucJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419360806","googleCitationCount":124,"googleAuthor":"S Ganatra"},{"title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","googleId":"nuUZaLcYH6QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310750","googleCitationCount":203,"googleAuthor":""},{"title":"Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast …","googleId":"wYsU2zHYLYsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609786","googleCitationCount":151,"googleAuthor":"S Loibl"},{"title":"CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced …","googleId":"9HCRc53DNvAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603893","googleCitationCount":174,"googleAuthor":"T Yau"},{"title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","googleId":"I8ZTgQgo1xcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312840","googleCitationCount":175,"googleAuthor":"J Mazieres"},{"title":"Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report","googleId":"Sl5_4RzRQsIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36387-0/pdf","googleCitationCount":221,"googleAuthor":"JM Michot"},{"title":"Novel patterns of response under immunotherapy","googleId":"GAMzWoEnEhoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931083X","googleCitationCount":122,"googleAuthor":"Y Kanjanapan"},{"title":"Correction to:“Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”","googleId":"XRWSwiszWlAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31151-2/abstract","googleCitationCount":156,"googleAuthor":""},{"title":"IMbrave150: efficacy and safety results from a ph III study evaluating atezolizumab (atezo)+ bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for …","googleId":"Jm2AXK-pY6EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582072","googleCitationCount":132,"googleAuthor":"P Galle"},{"title":"A decade of clinical development of PARP inhibitors in perspective","googleId":"y6ldpFWClDAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459851","googleCitationCount":112,"googleAuthor":"J Mateo"},{"title":"Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic","googleId":"lz277TZzAp8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398252","googleCitationCount":149,"googleAuthor":"A Sud"},{"title":"Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City","googleId":"pmM-tFJQxm4J","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7172785/","googleCitationCount":179,"googleAuthor":""},{"title":"Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy","googleId":"6M7ygNDwgRwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312293","googleCitationCount":132,"googleAuthor":"M Silva"},{"title":"ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour …","googleId":"OhOda1_-_qUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312694","googleCitationCount":129,"googleAuthor":"C Luchini"},{"title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","googleId":"HCWSEYGxVdoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312414","googleCitationCount":121,"googleAuthor":""},{"title":"Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer","googleId":"LrlT1bUzII8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312402","googleCitationCount":129,"googleAuthor":"AB Schrock"},{"title":"OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA …","googleId":"NaA7zsiFfF8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311111","googleCitationCount":141,"googleAuthor":"ME Robson"},{"title":"Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study","googleId":"yIEhPn-jRE8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310762","googleCitationCount":161,"googleAuthor":"S Loi"},{"title":"Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers","googleId":"rxpHSpgEVSQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312025","googleCitationCount":107,"googleAuthor":"NJ Birkbak"},{"title":"Managing COVID-19 in the oncology clinic and avoiding the distraction effect","googleId":"4cTsg-LBZ_oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36373-0/abstract","googleCitationCount":118,"googleAuthor":"M Bartoletti"},{"title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"GWGDRocMmTUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)32563-1/abstract","googleCitationCount":88,"googleAuthor":"PA Ascierto"},{"title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001","googleId":"AaDdn2x1JM8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312372","googleCitationCount":110,"googleAuthor":"GJ Riely"},{"title":"Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 …","googleId":"tw8SztNGAmoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459887","googleCitationCount":81,"googleAuthor":""},{"title":"European cancer mortality predictions for the year 2019 with focus on breast cancer","googleId":"JuabRO68Ai0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311561","googleCitationCount":103,"googleAuthor":"M Malvezzi"},{"title":"Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer","googleId":"fhrRhhCgghkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310816","googleCitationCount":105,"googleAuthor":"D Dong"},{"title":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","googleId":"o5vl8moVR8QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360580","googleCitationCount":98,"googleAuthor":"MC Liu"},{"title":"Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials","googleId":"p_bZDQKIRaAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311597","googleCitationCount":88,"googleAuthor":"DH Lee"},{"title":"Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the …","googleId":"aJ-Ko0Ibtj4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325527","googleCitationCount":78,"googleAuthor":""},{"title":"Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer","googleId":"q2NPQJHIb-wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312311","googleCitationCount":84,"googleAuthor":"MH Hong"},{"title":"IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) …","googleId":"oiOwkryJ6fMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603595","googleCitationCount":78,"googleAuthor":""},{"title":"Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed …","googleId":"m1ODQena_u8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310464","googleCitationCount":70,"googleAuthor":"S Lu"},{"title":"Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression","googleId":"AJ6vBhtPHH8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609841","googleCitationCount":63,"googleAuthor":"JF Gainor"},{"title":"ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research","googleId":"TfDayX7T_hMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459929","googleCitationCount":84,"googleAuthor":"C Marchiò"},{"title":"Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or …","googleId":"MtuPwyffdCMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310361","googleCitationCount":70,"googleAuthor":""},{"title":"PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous …","googleId":"WgptB7ZVt1wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603996","googleCitationCount":70,"googleAuthor":"J Mateo"},{"title":"How liquid biopsies can change clinical practice in oncology","googleId":"TtpBLXHkp8cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609725","googleCitationCount":55,"googleAuthor":"G Siravegna"},{"title":"Correction to:“Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”","googleId":"_3pKC04ni6sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31152-4/abstract","googleCitationCount":72,"googleAuthor":"A Vogel"},{"title":"A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer …","googleId":"f__GGZDtafkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312785","googleCitationCount":102,"googleAuthor":"S Loibl"},{"title":"ClarIDHy: a global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an …","googleId":"jfU-RHVtjGkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960387X","googleCitationCount":68,"googleAuthor":""},{"title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of> 2 …","googleId":"ubmiQDXRcIgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312104","googleCitationCount":81,"googleAuthor":"Y Fradet"},{"title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"keaXfXE_JPQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36394-8/pdf","googleCitationCount":44,"googleAuthor":"M Falconi"},{"title":"EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer","googleId":"sHKJXYmEJUUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312724","googleCitationCount":66,"googleAuthor":"HA Yu"},{"title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"bcTa42E45d4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)32555-2/abstract","googleCitationCount":84,"googleAuthor":"S Filetti"},{"title":"COVID-19 in patients with lung cancer","googleId":"lHxSTdF7C0QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342039894X","googleCitationCount":56,"googleAuthor":""},{"title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors","googleId":"SrujySyAX1QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310440","googleCitationCount":72,"googleAuthor":"N Steeghs"},{"title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by …","googleId":"fCfp8uuhvtQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310038","googleCitationCount":58,"googleAuthor":"G Pentheroudakis"},{"title":"TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer","googleId":"XH4YP-gxFQIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420359469","googleCitationCount":49,"googleAuthor":"GR Oxnard"},{"title":"The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?","googleId":"4roaPHV5OkEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609671","googleCitationCount":41,"googleAuthor":"A Elkrief"},{"title":"Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): final overall survival analysis","googleId":"iPUKuO-jOJIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604369","googleCitationCount":58,"googleAuthor":""},{"title":"Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up✰","googleId":"6sxlIn7jgPMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35465-1/abstract","googleCitationCount":32,"googleAuthor":"L Arcaini"},{"title":"OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer","googleId":"_9FpTDPFRjsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310294","googleCitationCount":68,"googleAuthor":"EA Blair"},{"title":"Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge","googleId":"Y_RnIY7LBNMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310245","googleCitationCount":57,"googleAuthor":"JM Loree"},{"title":"Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158","googleId":"SFv0W1jJUaIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594042","googleCitationCount":51,"googleAuthor":"MG Fakih"},{"title":"HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib","googleId":"6srZZ6G8ZiAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310774","googleCitationCount":56,"googleAuthor":""},{"title":"Severe immune-related adverse events are common with sequential PD-(L) 1 blockade and osimertinib","googleId":"k4fb_JXeXpgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311652","googleCitationCount":69,"googleAuthor":"AJ Schoenfeld"},{"title":"Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort …","googleId":"gbNFMnT5byAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360324","googleCitationCount":46,"googleAuthor":""},{"title":"Prevalence and mutational determinants of high tumor mutation burden in breast cancer","googleId":"dEErZ208wSoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419406984","googleCitationCount":37,"googleAuthor":"R Barroso-Sousa"},{"title":"Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 …","googleId":"2auh0-fIwtYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595217","googleCitationCount":43,"googleAuthor":"H Gogas"},{"title":"Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma","googleId":"zevF3PiDyUsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931227X","googleCitationCount":54,"googleAuthor":"YJL Jansen"},{"title":"Randomised efficacy and safety results for atezolizumab (Atezo)+ bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular …","googleId":"vDaSB3-vMv0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960390X","googleCitationCount":47,"googleAuthor":""},{"title":"Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study","googleId":"y851gSX83Z0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931035X","googleCitationCount":56,"googleAuthor":""},{"title":"Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019","googleId":"n-YQWNTmXLoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360737","googleCitationCount":37,"googleAuthor":"C Bosetti"},{"title":"Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant …","googleId":"vLCJ9MCArbMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325515","googleCitationCount":50,"googleAuthor":"G Bataillon"},{"title":"Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in …","googleId":"lSKLqWIqryIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311147","googleCitationCount":62,"googleAuthor":"WT Barry"},{"title":"Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"hqTJ9bBmyZUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)60977-4/abstract","googleCitationCount":40,"googleAuthor":"F Carneiro"},{"title":"Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting","googleId":"7RVfRil2YBcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609737","googleCitationCount":37,"googleAuthor":""},{"title":"FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)","googleId":"tzJq6OAr2FIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603911","googleCitationCount":45,"googleAuthor":"A Hollebecque"},{"title":"Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19","googleId":"DPJ-rk9FW2YJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/PMC7252166","googleCitationCount":48,"googleAuthor":""},{"title":"Identifying patients with NTRK fusion cancer","googleId":"_zVnDmJ_F8wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419551183","googleCitationCount":46,"googleAuthor":"JF Hechtman"},{"title":"TRK inhibitors in TRK fusion-positive cancers","googleId":"pbNES49JFCwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419551146","googleCitationCount":51,"googleAuthor":"A Drilon"},{"title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) …","googleId":"jkx2c8Pi3gsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312906","googleCitationCount":47,"googleAuthor":"T Sato"},{"title":"Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for …","googleId":"Djtj1qIVatgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309858","googleCitationCount":50,"googleAuthor":"YP Chen"},{"title":"Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal …","googleId":"oF-X3zRFY_wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603674","googleCitationCount":48,"googleAuthor":"S Chia"},{"title":"Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and …","googleId":"nT3V-MJosoEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325539","googleCitationCount":33,"googleAuthor":"U Dafni"},{"title":"Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after …","googleId":"4AdrvcxzRfAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310427","googleCitationCount":45,"googleAuthor":"SJ Luen"},{"title":"Timing of radiotherapy (RT) after radical prostatectomy (RP): first results from the RADICALS RT randomised controlled trial (RCT)","googleId":"_gO3PTzClp8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604023","googleCitationCount":43,"googleAuthor":"HG Kynaston"},{"title":"KEYNOTE-522: Phase III study of pembrolizumab (pembro)+ chemotherapy (chemo) vs placebo (pbo)+ chemo as neoadjuvant treatment, followed by pembro …","googleId":"wESk3ByKIIwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603637","googleCitationCount":43,"googleAuthor":"R Dent"},{"title":"Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer","googleId":"YgTrH2tOFsIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420326016","googleCitationCount":45,"googleAuthor":"F Saad"},{"title":"Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma","googleId":"ITC6lEts3YAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931004X","googleCitationCount":44,"googleAuthor":""},{"title":"Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium","googleId":"X7U2Z5pwlL0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311275","googleCitationCount":48,"googleAuthor":"R Alden"},{"title":"ESO–ESMO 4th International consensus guidelines for breast cancer in young women (BCY4)","googleId":"5OA652yhaLwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420363638","googleCitationCount":34,"googleAuthor":"F Cardoso"},{"title":"Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"EacC5X8DeNoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39932-4/abstract","googleCitationCount":29,"googleAuthor":""},{"title":"Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer","googleId":"XSoIvimC20kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459917","googleCitationCount":38,"googleAuthor":"B Lee"},{"title":"Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the …","googleId":"bTEH5zyfKmEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604370","googleCitationCount":37,"googleAuthor":"RS Herbst"},{"title":"Long-course preoperative chemoradiation versus 5× 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results …","googleId":"-ztpBsjY5VQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312967","googleCitationCount":48,"googleAuthor":"W Michalski"},{"title":"Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","googleId":"3bdR8-4wfLMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342039308X","googleCitationCount":37,"googleAuthor":"TK Choueiri"},{"title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","googleId":"95DDbU11eX0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399713","googleCitationCount":32,"googleAuthor":"J Remon"},{"title":"Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial","googleId":"zr4CoiyuQnAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310403","googleCitationCount":40,"googleAuthor":"RS Herbst"},{"title":"Surgery in reference centers improves survival of sarcoma patients: a nationwide study","googleId":"iWz5eFiC5KIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312323","googleCitationCount":45,"googleAuthor":"JY Blay"},{"title":"Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): post-hoc …","googleId":"0jR1BCf407QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603698","googleCitationCount":46,"googleAuthor":"S Loi"},{"title":"Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas …","googleId":"scNCVpsFdAAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325904","googleCitationCount":31,"googleAuthor":"V Makker"},{"title":"Testing for COVID-19 in lung cancer patients","googleId":"rGnGMrUMu8AJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39293-0/pdf","googleCitationCount":39,"googleAuthor":"S Peters"},{"title":"A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural …","googleId":"haiUYizilZ8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604515","googleCitationCount":37,"googleAuthor":""},{"title":"Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and …","googleId":"odR8Vk1w7u8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604382","googleCitationCount":34,"googleAuthor":""},{"title":"Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases","googleId":"HuF1PmDnk7EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310397","googleCitationCount":37,"googleAuthor":"A Bardelli"},{"title":"Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus","googleId":"gkwEA2X7cC0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399488","googleCitationCount":37,"googleAuthor":"S Banerjee"},{"title":"Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment …","googleId":"WAIpjOgnfGAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459954","googleCitationCount":47,"googleAuthor":"J Taieb"},{"title":"Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after …","googleId":"46IxcFkiSocJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30259-5/abstract","googleCitationCount":47,"googleAuthor":"TK Owonikoko"},{"title":"Adjuvant or salvage radiotherapy for the treatment of localised prostate cancer? A prospectively planned aggregate data meta-analysis","googleId":"hQu2ROH9aHQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604011","googleCitationCount":34,"googleAuthor":""},{"title":"Optimizing panel-based tumor mutational burden (TMB) measurement","googleId":"S1HxzZuQ0lgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459930","googleCitationCount":47,"googleAuthor":"J Budczies"},{"title":"Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer","googleId":"eziLk_KxKjYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603686","googleCitationCount":37,"googleAuthor":"H Wildiers"},{"title":"IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs …","googleId":"s2ZbG56JeBoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604072","googleCitationCount":35,"googleAuthor":"ID Davis"},{"title":"Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges","googleId":"m-l39GxGlyoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354675","googleCitationCount":24,"googleAuthor":"HM Kuerer"},{"title":"Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial","googleId":"DsYea6thfiUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311676","googleCitationCount":42,"googleAuthor":""},{"title":"Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a …","googleId":"Dtv_9UGKk2AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311184","googleCitationCount":42,"googleAuthor":"O Chinot"},{"title":"Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE …","googleId":"PfhwiaB7TbAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420364152","googleCitationCount":31,"googleAuthor":"T André"},{"title":"Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas","googleId":"n1EqoQcwYrQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342036018X","googleCitationCount":25,"googleAuthor":"AJ Schoenfeld"},{"title":"Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc …","googleId":"KcAJOZ_YqfwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420359275","googleCitationCount":32,"googleAuthor":""},{"title":"Crizotinib in c-MET-or ROS1-positive NSCLC: results of the AcSé phase II trial","googleId":"sqRXiDd8Py0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325606","googleCitationCount":42,"googleAuthor":"J Mazières"},{"title":"KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)","googleId":"9VGjLlghH7wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603704","googleCitationCount":33,"googleAuthor":""},{"title":"Targeting the PI3-kinase pathway in triple-negative breast cancer","googleId":"yltm_eoRTw4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312396","googleCitationCount":41,"googleAuthor":""},{"title":"Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate …","googleId":"IQkfwHD4KNsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590627","googleCitationCount":32,"googleAuthor":"D Campbell"},{"title":"First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma","googleId":"McdKD_h4194J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590329","googleCitationCount":42,"googleAuthor":"YY Janjigian"},{"title":"Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian …","googleId":"g34MC1v7YkUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604138","googleCitationCount":33,"googleAuthor":"IL Ray-Coquard"},{"title":"Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of …","googleId":"VEewJf0Hu6kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312827","googleCitationCount":33,"googleAuthor":""},{"title":"European cancer mortality predictions for the year 2020 with a focus on prostate cancer","googleId":"XzTgOemXGA4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360567","googleCitationCount":23,"googleAuthor":"P Bertuccio"},{"title":"Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy","googleId":"0OFd8l-6wQQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342036364X","googleCitationCount":21,"googleAuthor":"AM Menzies"},{"title":"A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): updated results","googleId":"7mOFh48MmssJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589633","googleCitationCount":35,"googleAuthor":"J Llovet"},{"title":"Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More …","googleId":"zmzE8yWnucEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325898","googleCitationCount":25,"googleAuthor":"JMS Bartlett"},{"title":"CTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC","googleId":"9vGOynXF3HQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596880","googleCitationCount":32,"googleAuthor":""},{"title":"Efficacy of PI3K inhibitors in advanced breast cancer","googleId":"fpx7lM_LjGEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342034374X","googleCitationCount":35,"googleAuthor":"F Andre"},{"title":"Context matters—consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials","googleId":"YxGnAiwPREoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311317","googleCitationCount":34,"googleAuthor":"E Fontana"},{"title":"How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer","googleId":"5-2L4DxJ1PAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312037","googleCitationCount":32,"googleAuthor":"S Peters"},{"title":"Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants","googleId":"iRLLQHPhEfIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312049","googleCitationCount":31,"googleAuthor":"C Ay"},{"title":"JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with …","googleId":"TpO_JrFmmc8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420363869","googleCitationCount":16,"googleAuthor":"G Pentheroudakis"},{"title":"Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized …","googleId":"vdJ68Hd32cgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419360788","googleCitationCount":22,"googleAuthor":"AS Mansfield"},{"title":"Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?","googleId":"IKVOgxvMniQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459875","googleCitationCount":46,"googleAuthor":"S Heeke"},{"title":"A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood","googleId":"XJ0zydUFezMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419390842","googleCitationCount":19,"googleAuthor":"A Califano"},{"title":"A randomized phase II/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer","googleId":"ftZkpvQEy4gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604187","googleCitationCount":30,"googleAuthor":"W Brady"},{"title":"Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase …","googleId":"ldY6Wor-mcsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325576","googleCitationCount":37,"googleAuthor":"J Mizusawa"},{"title":"Atypical lung feature on chest CT in a lung adenocarcinoma cancer patient infected with COVID-19","googleId":"Wxh0euKHR5oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36080-4/pdf","googleCitationCount":32,"googleAuthor":""},{"title":"Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours","googleId":"Tgqxylw0bP4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586689","googleCitationCount":33,"googleAuthor":"MG Fakih"},{"title":"Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines","googleId":"Dhb1MBgBk1cJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42448-2/abstract","googleCitationCount":16,"googleAuthor":"M Lambertini"},{"title":"A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with …","googleId":"XTj-dKLPALQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603601","googleCitationCount":30,"googleAuthor":""},{"title":"Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors","googleId":"c5uc3zECzYoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312281","googleCitationCount":35,"googleAuthor":"MD Hellmann"},{"title":"Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish …","googleId":"7v36ISbrmggJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311081","googleCitationCount":30,"googleAuthor":"R Garcia-Sanz"},{"title":"Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"vHGSYVVrN1kJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36079-8/fulltext","googleCitationCount":14,"googleAuthor":"Y Ofran"},{"title":"Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II …","googleId":"Xi6pgvJcNVAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609816","googleCitationCount":24,"googleAuthor":""},{"title":"A segregated-team model to maintain cancer care during the COVID-19 outbreak at an academic center in Singapore.","googleId":"_odR_iob2lcJ","googleLink":"https://europepmc.org/article/pmc/pmc7174823","googleCitationCount":34,"googleAuthor":""},{"title":"Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions","googleId":"G2AOastoQf8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419621721","googleCitationCount":33,"googleAuthor":""},{"title":"Man against machine reloaded: performance of a market-approved convolutional neural network in classifying a broad spectrum of skin lesions in comparison …","googleId":"-kDojCbHCYcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354687","googleCitationCount":24,"googleAuthor":"W Stolz"},{"title":"Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the …","googleId":"wu2l1553meYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31045-2/abstract","googleCitationCount":39,"googleAuthor":"S Peters"},{"title":"Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA","googleId":"RVX2Q5TKAzEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931155X","googleCitationCount":28,"googleAuthor":"S Sandhu"},{"title":"BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with …","googleId":"bF6-xN0csoQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311718","googleCitationCount":27,"googleAuthor":""},{"title":"Pre-specified interim analysis of GALAHAD: a phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and …","googleId":"QaKgNGYqg6AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604035","googleCitationCount":30,"googleAuthor":"MR Smith"},{"title":"Biological background of the genomic variations of cf-DNA in healthy individuals","googleId":"Vl0F2c7sxd4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310737","googleCitationCount":30,"googleAuthor":""},{"title":"Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in …","googleId":"Y27Ab4e_nEEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960983X","googleCitationCount":22,"googleAuthor":"G Villacampa"},{"title":"Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast …","googleId":"qxb0mfJK-zsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311615","googleCitationCount":33,"googleAuthor":""},{"title":"Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications","googleId":"8-5nGcFfh-IJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931244X","googleCitationCount":32,"googleAuthor":"B Surmann"},{"title":"Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations","googleId":"ugBFpA5s_MgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341936079X","googleCitationCount":23,"googleAuthor":"J Mazieres"},{"title":"Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): initial results from the MOUNTAINEER trial","googleId":"vuVmkjkJ76AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587488","googleCitationCount":28,"googleAuthor":"A Cercek"},{"title":"Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial","googleId":"WNw8KdGG1d8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311950","googleCitationCount":26,"googleAuthor":"I Garcia-Murillas"},{"title":"Registrational results of LOXO-292 in patients with RET-altered thyroid cancers","googleId":"0-t99iZiuDYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604539","googleCitationCount":26,"googleAuthor":"A Drilon"},{"title":"Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized …","googleId":"8FF-j098uYEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354638","googleCitationCount":22,"googleAuthor":"DE Magee"},{"title":"Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment","googleId":"agJEFPIBxlUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36077-4/pdf","googleCitationCount":16,"googleAuthor":""},{"title":"Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment …","googleId":"O-BA9Uz0KpgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603790","googleCitationCount":30,"googleAuthor":"J Taieb"},{"title":"Intratumoral IL17-producing cells infiltration correlate with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer","googleId":"3EZHtU2FiRAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310233","googleCitationCount":30,"googleAuthor":""},{"title":"Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors","googleId":"stJ-r3IG89wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342032562X","googleCitationCount":33,"googleAuthor":"J Vardy"},{"title":"Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group","googleId":"ShcmN2lrzUAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312700","googleCitationCount":31,"googleAuthor":"M Donoghue"},{"title":"HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L) 1 blockade in advanced non-small …","googleId":"IiJECdi4WTIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420392954","googleCitationCount":18,"googleAuthor":"HS Kim"},{"title":"Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast …","googleId":"aPOX45bC4y0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310877","googleCitationCount":29,"googleAuthor":"AA Brandes"},{"title":"Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized …","googleId":"js2-M_CPsvEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311585","googleCitationCount":30,"googleAuthor":""},{"title":"Overall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+ trastuzumab emtansine (T-DM1) vs …","googleId":"Mg52z8zrtAgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585271","googleCitationCount":29,"googleAuthor":"LA Emens"},{"title":"Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives","googleId":"flJXLGG9SjQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354146","googleCitationCount":20,"googleAuthor":"D Ciardiello"},{"title":"Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K …","googleId":"3xJWImk5ue0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420343726","googleCitationCount":25,"googleAuthor":"D Eiger"},{"title":"Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial","googleId":"vFcPTKK-fD0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420363742","googleCitationCount":25,"googleAuthor":""},{"title":"FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer","googleId":"IhQez76oQiEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312918","googleCitationCount":25,"googleAuthor":"P Nuciforo"},{"title":"Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite …","googleId":"x98I5RIl2xEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603959","googleCitationCount":27,"googleAuthor":"K Shitara"},{"title":"Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression≥ 50%","googleId":"4ppXofhhqZMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419417213","googleCitationCount":19,"googleAuthor":"JF Gainor"},{"title":"Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","googleId":"ZWpnw0ZzBBQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310920","googleCitationCount":33,"googleAuthor":""},{"title":"Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy …","googleId":"mkEum991BwIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931230X","googleCitationCount":23,"googleAuthor":""},{"title":"PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from …","googleId":"b3kGa1DtEb8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604497","googleCitationCount":22,"googleAuthor":"MC Garassino"},{"title":"COVID-19 infection in cancer patients: early observations and unanswered questions","googleId":"1wS454AcwJMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36384-5/pdf","googleCitationCount":26,"googleAuthor":""},{"title":"Gender medicine and oncology: report and consensus of an ESMO workshop","googleId":"NxybZTWA4R0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325643","googleCitationCount":25,"googleAuthor":"S Oertelt-Prigione"},{"title":"Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients","googleId":"6tfIGvxzDlcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311640","googleCitationCount":28,"googleAuthor":"JH Lee"},{"title":"Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis","googleId":"MwOJQ9vxOyEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325941","googleCitationCount":27,"googleAuthor":"AR Ferreira"},{"title":"Phase II study of olaparib (O) and durvalumab (D)(MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast …","googleId":"TydcdbeVsAsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594030","googleCitationCount":23,"googleAuthor":"S Postel-Vinay"},{"title":"Overview of the relevance of PI3K pathway in HR-positive breast cancer","googleId":"r3cKMq3JT7EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420343738","googleCitationCount":24,"googleAuthor":"N Vasan"},{"title":"Recent advances in circulating nucleic acids in oncology","googleId":"llW4tJsV08sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310919","googleCitationCount":27,"googleAuthor":""},{"title":"MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy …","googleId":"KXK8bYznZqIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603728","googleCitationCount":21,"googleAuthor":""},{"title":"Molecular pathology of tumors of the central nervous system","googleId":"-OSUrllH0x0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312839","googleCitationCount":28,"googleAuthor":""},{"title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative …","googleId":"tFwE2CDFyu4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310002","googleCitationCount":23,"googleAuthor":"F Lordick"},{"title":"Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial","googleId":"LIsqyzgs5LIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420363808","googleCitationCount":16,"googleAuthor":"R Berardi"},{"title":"Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo","googleId":"UJPt7EO5QPwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398367","googleCitationCount":13,"googleAuthor":"T Karn"},{"title":"French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak","googleId":"7KKlQ2brJZ0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36413-9/pdf","googleCitationCount":19,"googleAuthor":"S Bonvalot"},{"title":"Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer","googleId":"sWJkGW2cAN0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459942","googleCitationCount":28,"googleAuthor":"J Zhang"},{"title":"Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications","googleId":"8Lhub5gERssJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459814","googleCitationCount":20,"googleAuthor":"R Nicolle"},{"title":"BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab …","googleId":"_pbYZDbSygEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30959-7/abstract","googleCitationCount":25,"googleAuthor":"S Kopetz"},{"title":"Extrachromosomal DNA–relieving heredity constraints, accelerating tumour evolution","googleId":"hbrHEmWXqcQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420363924","googleCitationCount":12,"googleAuthor":"C Bailey"},{"title":"Evolutionary dynamics of residual disease in human glioblastoma","googleId":"2tBZ5ry8hPEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310725","googleCitationCount":23,"googleAuthor":"G Caravagna"},{"title":"Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta …","googleId":"8eJgY7p9cccJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419390854","googleCitationCount":14,"googleAuthor":"A Athanasiou"},{"title":"Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label …","googleId":"lyFoqwPuSNEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420364346","googleCitationCount":17,"googleAuthor":"RL Ferris"},{"title":"Phase II study of olaparib+ durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)","googleId":"FfyCXormmyoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594029","googleCitationCount":21,"googleAuthor":""},{"title":"REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer …","googleId":"0IyMIZT1uYUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310336","googleCitationCount":25,"googleAuthor":"K Shitara"},{"title":"Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC","googleId":"jQjwSZkTEPgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603984","googleCitationCount":25,"googleAuthor":"DG Duda"},{"title":"Phase II study of pertuzumab and trastuzumab-emtansine (T-DM1) in patients with HER2-positive metastatic colorectal cancer: The HERACLES-B (HER2 …","googleId":"xnKXuBOa33kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603844","googleCitationCount":20,"googleAuthor":"A Sartore-Bianchi"},{"title":"Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer","googleId":"YFb0XUsUREUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419580139","googleCitationCount":17,"googleAuthor":"D Hyman"},{"title":"Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer","googleId":"_enP7C4XwBgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360555","googleCitationCount":18,"googleAuthor":"O Cohen"},{"title":"Efficacy and safety of nivolumab (Nivo)+ ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: results from CheckMate 358","googleId":"zMFU0IFcgp8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604199","googleCitationCount":21,"googleAuthor":"RW Naumann"},{"title":"Deep learning radiomic nomogram can predict the number of lymph node metastasis in locally advanced gastric cancer: an international multicenter study","googleId":"cc7yeXPHCcUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420392942","googleCitationCount":16,"googleAuthor":"D Dong"},{"title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS …","googleId":"ABZjXaoc-0gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419532240","googleCitationCount":13,"googleAuthor":"G Pentheroudakis"},{"title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the …","googleId":"cvwh9Cb_5EAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420397969","googleCitationCount":24,"googleAuthor":""},{"title":"The forefront of ovarian cancer therapy: update on PARP inhibitors","googleId":"A2wPDo9ojcQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398914","googleCitationCount":19,"googleAuthor":"MR Mirza"},{"title":"An adaptive, biomarker directed platform study in metastatic urothelial cancer (BISCAY) with durvalumab in combination with targeted therapies","googleId":"nnpcydVVlxkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591189","googleCitationCount":19,"googleAuthor":"R Jones"},{"title":"Preserving fertility in female patients with hematological malignancies: a multidisciplinary oncofertility approach","googleId":"x1D2NaIvnm0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325862","googleCitationCount":14,"googleAuthor":"A Anazodo"},{"title":"LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC …","googleId":"w-nteMbYxsQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42378-6/abstract","googleCitationCount":39,"googleAuthor":"K Shitara"},{"title":"696O_PR Nivolumab+ cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER …","googleId":"LOeyRQQr1TEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42339-7/abstract","googleCitationCount":37,"googleAuthor":"TK Choueiri"},{"title":"Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for …","googleId":"smZ_tgrg7msJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310257","googleCitationCount":21,"googleAuthor":""},{"title":"Pre-operative ipilimumab and nivolumab in locoregionally advanced, stage III, urothelial cancer (NABUCCO)","googleId":"7e4fZViTeOkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591207","googleCitationCount":17,"googleAuthor":""},{"title":"Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers","googleId":"UlTYYiNbI9EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312384","googleCitationCount":24,"googleAuthor":"K Nones"},{"title":"Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung …","googleId":"8z2OHoHDekkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311603","googleCitationCount":22,"googleAuthor":""},{"title":"The Macrophage 'Do not eat me'signal, CD47, is a clinically validated cancer immunotherapy target","googleId":"ld6xbcHXvWcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31086-5/abstract","googleCitationCount":22,"googleAuthor":""},{"title":"Liquid biopsy assay for lung carcinoma using centrifuged supernatants from fine-needle aspiration specimens","googleId":"grujUqpfw64J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311974","googleCitationCount":19,"googleAuthor":"W Ye"},{"title":"Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer","googleId":"lNFfQDkVvhIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419551171","googleCitationCount":21,"googleAuthor":"A Amatu"},{"title":"Head and neck cancer prevention: from primary prevention to impact of clinicians on reducing burden","googleId":"dqOK4yydhNEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311706","googleCitationCount":22,"googleAuthor":""},{"title":"IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo)+ carboplatin+ etoposide in extensive-stage SCLC (ES-SCLC)","googleId":"xdN7rYsjtF8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419598702","googleCitationCount":30,"googleAuthor":"AS Mansfield"},{"title":"De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study","googleId":"ZhfooX04w4QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311937","googleCitationCount":26,"googleAuthor":""},{"title":"Tailored immunotherapy approach with nivolumab in advanced renal cell carcinoma (TITAN-RCC)","googleId":"a2ySe8Qr7Z8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604114","googleCitationCount":25,"googleAuthor":"MO Grimm"},{"title":"Risk profiling based on p16 and HPV DNA more accurately predicts location of disease relapse in patients with oropharyngeal squamous cell carcinoma","googleId":"ueg1xNLivs4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311093","googleCitationCount":17,"googleAuthor":"JH Rasmussen"},{"title":"INVICTUS: a Phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as≥ 4th-line therapy in patients with …","googleId":"DYN4OGko_wYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604473","googleCitationCount":19,"googleAuthor":"H Gelderblom"},{"title":"Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma","googleId":"2GN65pCEtmUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354067","googleCitationCount":13,"googleAuthor":"S Ugurel"},{"title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on adjuvant therapy","googleId":"jRlAdvzt20cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604205","googleCitationCount":17,"googleAuthor":""},{"title":"Advances in targeted alpha therapy for prostate cancer","googleId":"qeZvW6dmJH4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325850","googleCitationCount":14,"googleAuthor":"G De Vincentis"},{"title":"Management of hepatocellular carcinoma in the time of COVID-19","googleId":"v5bGX8EiKCwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39304-2/abstract","googleCitationCount":17,"googleAuthor":"M Iavarone"},{"title":"Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of …","googleId":"MSh6nWxhVTkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311159","googleCitationCount":20,"googleAuthor":"L Danilova"},{"title":"Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for …","googleId":"Ly-xjGYuG7wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604412","googleCitationCount":16,"googleAuthor":"V Velcheti"},{"title":"Epigenetic modulations and lineage plasticity in advanced prostate cancer","googleId":"UZi_jLmBMpwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360348","googleCitationCount":13,"googleAuthor":"R Montironi"},{"title":"Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer","googleId":"F6TcQAXKdLkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419390945","googleCitationCount":24,"googleAuthor":"A Lusque"},{"title":"Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small …","googleId":"52y4nZCSp3UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419581212","googleCitationCount":17,"googleAuthor":""},{"title":"Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer","googleId":"lS8eu5BjU1IJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309998","googleCitationCount":21,"googleAuthor":"YX Feng"},{"title":"Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China","googleId":"o7MGi_c7O-EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609750","googleCitationCount":14,"googleAuthor":""},{"title":"Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer","googleId":"9rmS9po1tKgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325989","googleCitationCount":24,"googleAuthor":""},{"title":"Triumph: primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (PTS) with metastatic colorectal cancer (mCRC) with HER2 …","googleId":"n9BfcJJvHrIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587476","googleCitationCount":20,"googleAuthor":"Y Nakamura"},{"title":"The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer","googleId":"42c2AQFuvg0J","googleLink":"https://www.researchgate.net/profile/Gianluca_Masi/publication/334295334_O-013Impact_of_age_and_gender_on_safety_and_efficacy_of_first-line_FOLFOXIRIbevacizumab_in_mCRC_a_pooled_analysis_of_TRIBE_and_TRIBE2_studies/links/5dd2cbc3299bf1b74b4e18ec/O-013Impact-of-age-and-gender-on-safety-and-efficacy-of-first-line-FOLFOXIRI-bevacizumab-in-mCRC-a-pooled-analysis-of-TRIBE-and-TRIBE2-studies.pdf","googleCitationCount":19,"googleAuthor":"M Shah"},{"title":"MONARCH 2: overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2-advanced breast cancer","googleId":"PVTN2slrZ5QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603662","googleCitationCount":18,"googleAuthor":"J Sohn"},{"title":"Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the …","googleId":"TuSfcSrt8BYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591268","googleCitationCount":17,"googleAuthor":"TK Choueiri"},{"title":"Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients","googleId":"FLQZU05i39wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398732","googleCitationCount":10,"googleAuthor":"Y Nakamura"},{"title":"Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma","googleId":"6b-CHagAf4oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311986","googleCitationCount":17,"googleAuthor":"J Yu"},{"title":"Current status of immune checkpoint inhibition in early-stage NSCLC","googleId":"F5k74PO6DsAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931289X","googleCitationCount":20,"googleAuthor":""},{"title":"ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer","googleId":"acxHqv6UDloJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360415","googleCitationCount":16,"googleAuthor":"S Orlov"},{"title":"An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial)","googleId":"6Zw2I3UKrooJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309810","googleCitationCount":21,"googleAuthor":""},{"title":"Randomized phase III ANGEL study of rivoceranib (apatinib)+ best supportive care (BSC) vs placebo+ BSC in patients with advanced/metastatic gastric …","googleId":"1A8_QawQBrMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603947","googleCitationCount":19,"googleAuthor":"YK Kang"},{"title":"A randomized phase III trial comparing primary tumor resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: Updated results …","googleId":"KI1-fpoSKj8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40538-1/abstract","googleCitationCount":18,"googleAuthor":"K Shitara"},{"title":"Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic …","googleId":"7hFAPDMoQdsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309792","googleCitationCount":20,"googleAuthor":"G Bodoky"},{"title":"Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study","googleId":"ouf4Iu9Igh4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419417249","googleCitationCount":9,"googleAuthor":"R Kurzrock"},{"title":"Multicenter randomized controlled trial to evaluate the efficacy and tolerability of frozen gloves for the prevention of chemotherapy-induced peripheral …","googleId":"NPgTkgPAclkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354080","googleCitationCount":12,"googleAuthor":"F Mols"},{"title":"Nivolumab (NIVO)+ low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung …","googleId":"M1pTCaU6dAYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604357","googleCitationCount":15,"googleAuthor":"S Peters"},{"title":"Pilot randomized trial of an electronic symptom monitoring intervention for hospitalized patients with cancer","googleId":"58qX7XXIVQgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931021X","googleCitationCount":17,"googleAuthor":"RD Nipp"},{"title":"FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus …","googleId":"yvVADTcEIYAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419592055","googleCitationCount":15,"googleAuthor":"N Colombo"},{"title":"Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal …","googleId":"rrb4MMBTzvUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311160","googleCitationCount":18,"googleAuthor":""},{"title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","googleId":"2c57VdqfLgkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420421647","googleCitationCount":7,"googleAuthor":"V Serra"},{"title":"Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy","googleId":"X3FpqKpxPOQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312438","googleCitationCount":22,"googleAuthor":""},{"title":"Meeting report from the joint IARC–NCI International cancer seminar series: a focus on colorectal cancer","googleId":"DsrZK-Rp-gUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311251","googleCitationCount":17,"googleAuthor":"MJ Gunter"},{"title":"Pembrolizumab in microsatellite instability high cancers: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies","googleId":"swBGN60j_j8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593863","googleCitationCount":15,"googleAuthor":"D Le"},{"title":"Initial results from TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients (Pts) with metastatic urothelial cancer (mUC) after failure of …","googleId":"iIQVL6SPcWkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604096","googleCitationCount":15,"googleAuthor":"N Agarwal"},{"title":"Perioperative chemotherapy of oxaliplatin combined with S-1 (SOX) versus postoperative chemotherapy of SOX or oxaliplatin with capecitabine (XELOX) in …","googleId":"Nyb_mj5OEWoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603935","googleCitationCount":20,"googleAuthor":""},{"title":"Differential effects of an electronic symptom monitoring intervention based on the age of patients with advanced cancer","googleId":"NKeaDsv_3u4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354043","googleCitationCount":11,"googleAuthor":"RD Nipp"},{"title":"Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib","googleId":"M-zIDvNotN8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342032559X","googleCitationCount":12,"googleAuthor":"P Hammel"},{"title":"Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer …","googleId":"I0p5ITwTiz4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310373","googleCitationCount":17,"googleAuthor":"PM Webb"},{"title":"Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas","googleId":"tgqXxm9e9RMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420393108","googleCitationCount":7,"googleAuthor":"LK de Klerk"},{"title":"Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer","googleId":"2OoMY_m35EEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354092","googleCitationCount":12,"googleAuthor":"D De Ruysscher"},{"title":"Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion","googleId":"SIU1amTP2bwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419551195","googleCitationCount":21,"googleAuthor":"EM O'reilly"},{"title":"LBA43 spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic …","googleId":"7WMCEEMWtEwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42355-5/abstract","googleCitationCount":12,"googleAuthor":"GV Long"},{"title":"A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal …","googleId":"rtNp8qsBolcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399270","googleCitationCount":14,"googleAuthor":"S Park"},{"title":"KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for …","googleId":"UIRHWToeoOoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420345506","googleCitationCount":13,"googleAuthor":""},{"title":"5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+ IPI) combination therapy in advanced melanoma","googleId":"3GXbb48SKIEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604254","googleCitationCount":11,"googleAuthor":"JMG Larkin"},{"title":"Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for …","googleId":"uKQP4Wz61dgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325540","googleCitationCount":16,"googleAuthor":""},{"title":"Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind …","googleId":"5IIjn9Orx44J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398392","googleCitationCount":10,"googleAuthor":"I Borbath"},{"title":"Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An …","googleId":"cZ5XBovNdmwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604102","googleCitationCount":14,"googleAuthor":"RS Kaplan"},{"title":"Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients","googleId":"oxFPf2cdQdwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420359251","googleCitationCount":18,"googleAuthor":"A Algazi"},{"title":"Timing of HPV16-E6 antibody seroconversion before OPSCC: findings from the HPVC3 consortium","googleId":"8FMktI4iiF8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312712","googleCitationCount":17,"googleAuthor":""},{"title":"Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with∼ …","googleId":"qSPVtGMofikJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360191","googleCitationCount":16,"googleAuthor":"A Knuppel"},{"title":"Prognostic gene expression signature for high-grade serous ovarian cancer","googleId":"A2_DJVg4SMYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398410","googleCitationCount":11,"googleAuthor":"J Millstein"},{"title":"Simultaneous multi-cancer detection and tissue of origin (TOO) localization using targeted bisulfite sequencing of plasma cell-free DNA (cfDNA)","googleId":"BzXj6JTEc9EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604345","googleCitationCount":14,"googleAuthor":"GR Oxnard"},{"title":"EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort …","googleId":"DKytDmeaZZMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325928","googleCitationCount":21,"googleAuthor":"J Bellmunt"},{"title":"Does androgen deprivation therapy protect against severe complications from COVID-19?","googleId":"R1H_v4qaLfQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39933-6/abstract","googleCitationCount":13,"googleAuthor":"X Zhong"},{"title":"Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial","googleId":"3LMeyIHHBPYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582254","googleCitationCount":14,"googleAuthor":"HR Kim"},{"title":"The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB)≥ 10: a decision centered on empowering patients and their …","googleId":"D7CdjGBq4Q4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534%2820%2939936-1/fulltext","googleCitationCount":13,"googleAuthor":"V Subbiah"},{"title":"Cancer mortality in Europe in 2015 and an overview of trends since 1990","googleId":"DmXfIFSav7MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312931","googleCitationCount":12,"googleAuthor":"P Bertuccio"},{"title":"Integrating postradiotherapy plasma Epstein–Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy","googleId":"07zg0H1-SUYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420363766","googleCitationCount":10,"googleAuthor":"BB Ma"},{"title":"Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer","googleId":"Ss2zX1CeqbQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310749","googleCitationCount":18,"googleAuthor":"AM Ben-David"},{"title":"CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors","googleId":"-U42AytoZk0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590615","googleCitationCount":14,"googleAuthor":"ES Antonarakis"},{"title":"Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer","googleId":"FfvSFLjg4xsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420424652","googleCitationCount":8,"googleAuthor":""},{"title":"Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK …","googleId":"XQR-ImLJkfIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325953","googleCitationCount":29,"googleAuthor":"HJ Lenz"},{"title":"Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer","googleId":"WI68VFTWPK4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310798","googleCitationCount":18,"googleAuthor":"R Sundar"},{"title":"Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation–positive melanoma …","googleId":"9xXOv_5K8hAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354079","googleCitationCount":9,"googleAuthor":"PA Ascierto"},{"title":"Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer","googleId":"aLbkOt9viK0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360786","googleCitationCount":12,"googleAuthor":"G Lamberti"},{"title":"A systematic review and meta-analysis of the 2007 WCRF/AICR score in relation to cancer-related health outcomes","googleId":"J8z9-MWXHUsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420319219","googleCitationCount":12,"googleAuthor":""},{"title":"3-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo) adjuvant ipilimumab (IPI)+ nivolumab (NIVO) in macroscopic stage III …","googleId":"EIlLpk01leoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595242","googleCitationCount":13,"googleAuthor":"CU Blank"},{"title":"LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non …","googleId":"E7cPqiQtX3UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342034549X","googleCitationCount":12,"googleAuthor":"RS Herbst"},{"title":"Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: Initial results from the ALK+ cohort","googleId":"QDf00-oG_A0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604394","googleCitationCount":17,"googleAuthor":"S Peters"},{"title":"Phase III randomized study of neoadjuvant chemotherapy (CT) with docetaxel (D), oxaliplatin (O) and S-1 (S)(DOS) followed by surgery and adjuvant S-1, vs …","googleId":"Td3McEwog0kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603923","googleCitationCount":16,"googleAuthor":"YK Kang"},{"title":"Primary 2-year (yr) results of a phase II, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant …","googleId":"MZkk_g1ZvK0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604230","googleCitationCount":12,"googleAuthor":"DE Gyorki"},{"title":"TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers","googleId":"XRSQh-bBR4EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587282","googleCitationCount":13,"googleAuthor":"A Drilon"},{"title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","googleId":"DiJw6z1VjykJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42460-3/abstract","googleCitationCount":27,"googleAuthor":"F Cardoso"},{"title":"A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ …","googleId":"fRhXJknAZ0cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311949","googleCitationCount":18,"googleAuthor":"J Veeraraghavan"},{"title":"Complementary roles of MRI and endoscopic examination in the early detection of nasopharyngeal carcinoma","googleId":"R2Qwv5iK2DUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312001","googleCitationCount":14,"googleAuthor":"AD King"},{"title":"Development of adaptive immune effector therapies in solid tumors","googleId":"pn7jB1r8bZIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325874","googleCitationCount":10,"googleAuthor":"F Lanza"},{"title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO …","googleId":"dUGfUJzYiOsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419360831","googleCitationCount":7,"googleAuthor":"KH Lee"},{"title":"Bone health in cancer: ESMO clinical practice guidelines","googleId":"yjXVVOyuOQIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39995-6/abstract","googleCitationCount":14,"googleAuthor":"R Coleman"},{"title":"Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and …","googleId":"rhmbclHXLbcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39938-5/abstract","googleCitationCount":6,"googleAuthor":"F Cardoso"},{"title":"Neuronal autoantibodies associated with cognitive impairment in melanoma patients","googleId":"ZfHJQDb-fMYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931169X","googleCitationCount":16,"googleAuthor":""},{"title":"Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket'trial","googleId":"pi-01BkZC7QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30513-7/abstract","googleCitationCount":17,"googleAuthor":"J Harding"},{"title":"Pembrolizumab (pembro)+ chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in …","googleId":"L7XK79b7QqIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604400","googleCitationCount":13,"googleAuthor":""},{"title":"BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) …","googleId":"u-bpLVJKA18J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587543","googleCitationCount":11,"googleAuthor":"TR Halfdanarson"},{"title":"Cancer mortality in the elderly in 11 countries worldwide, 1970–2015","googleId":"9nB-JV49mk4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931292X","googleCitationCount":11,"googleAuthor":"M Malvezzi"},{"title":"Interpretation of time-to-event outcomes in randomized trials: an online randomized experiment","googleId":"QrolSTmxn5IJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309809","googleCitationCount":16,"googleAuthor":"IR Weir"},{"title":"Body size and obesity during adulthood, and risk of lympho-haematopoietic cancers: an update of the WCRF-AICR systematic review of published prospective …","googleId":"W4mtmUjUBisJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311263","googleCitationCount":15,"googleAuthor":"L Abar"},{"title":"Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients …","googleId":"rVaraWt_ov4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420397982","googleCitationCount":12,"googleAuthor":"F André"},{"title":"Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence …","googleId":"rKo_d3VxsaYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604242","googleCitationCount":10,"googleAuthor":"D Schadendorf"},{"title":"EV-103: initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma","googleId":"LjYPNpazzngJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591177","googleCitationCount":12,"googleAuthor":""},{"title":"LBA3 Nivolumab (NIVO)+ platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC …","googleId":"UB47kBIJdJ8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342034552X","googleCitationCount":10,"googleAuthor":""},{"title":"Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors","googleId":"NENwnyRoHAoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399282","googleCitationCount":8,"googleAuthor":"F Meric-Bernstam"},{"title":"Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath","googleId":"YhpGzTX_1DcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609828","googleCitationCount":17,"googleAuthor":"M Muller"},{"title":"Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) …","googleId":"wEhNMgAOtrQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30051-1/abstract","googleCitationCount":16,"googleAuthor":""},{"title":"Noninvasive imaging evaluation of tumor immune microenvironment to predict outcomes in gastric cancer","googleId":"PwNrlAJv6UUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420363821","googleCitationCount":7,"googleAuthor":"Y Jiang"},{"title":"Measures of body fatness and height in early and mid-to-late adulthood and prostate cancer: risk and mortality in The Pooling Project of Prospective Studies of …","googleId":"kvlFRvbPn1sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354134","googleCitationCount":8,"googleAuthor":"JM Genkinger"},{"title":"A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower …","googleId":"jvU9psOBTO4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459905","googleCitationCount":19,"googleAuthor":"O Türeci"},{"title":"Clinical development of therapies targeting TGFβ: current knowledge and future perspectives.","googleId":"R1UXAr4PW90J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399464","googleCitationCount":5,"googleAuthor":"D Ciardiello"},{"title":"Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials","googleId":"Nz2kQiOi_LgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354110","googleCitationCount":10,"googleAuthor":""},{"title":"811MO maintenance olaparib for patients (PTS) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (Y) follow-up (f/u) from …","googleId":"oi9w_cO8PGsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40946-9/abstract","googleCitationCount":11,"googleAuthor":"N Colombo"},{"title":"Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a …","googleId":"v-VNA55SDYYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311226","googleCitationCount":18,"googleAuthor":"Y Bi"},{"title":"Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to …","googleId":"KOG_AcRQSzsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596867","googleCitationCount":11,"googleAuthor":""},{"title":"Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the …","googleId":"ZfAaBXFIBvIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420421064","googleCitationCount":8,"googleAuthor":""},{"title":"Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor","googleId":"vrXLOmpkcssJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31280-3/abstract","googleCitationCount":14,"googleAuthor":"JY Blay"},{"title":"Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: pooled analysis of KEYNOTE-001 …","googleId":"Xn06f8Ktfq0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596909","googleCitationCount":11,"googleAuthor":"AS Mansfield"},{"title":"Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147)(Alliance)","googleId":"CpTWaK4cMO8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420359445","googleCitationCount":7,"googleAuthor":"TC Smyrk"},{"title":"Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) …","googleId":"7OjVEeecLcYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604266","googleCitationCount":12,"googleAuthor":"H Gogas"},{"title":"Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407","googleId":"whQ4QbeLsfYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596910","googleCitationCount":14,"googleAuthor":""},{"title":"On the need to adjust for multiplicity in confirmatory clinical trials with master protocols","googleId":"YN3bWWuIEqMJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6503623/","googleCitationCount":13,"googleAuthor":""},{"title":"Identification of an excellent prognosis subset of human papillomavirus-associated oropharyngeal cancer patients by quantification of intratumoral CD103+ …","googleId":"HHxIrzN0D90J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609804","googleCitationCount":8,"googleAuthor":"RJ Young"},{"title":"ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee","googleId":"TDALFMKmFZIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399397","googleCitationCount":5,"googleAuthor":"PA Ascierto"},{"title":"Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients","googleId":"FnoShPpOI6MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420393066","googleCitationCount":5,"googleAuthor":"P Razavi"},{"title":"Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from> 4000 men with metastatic castration …","googleId":"h-isco5sVRMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590639","googleCitationCount":10,"googleAuthor":"JS de Bono"},{"title":"Three-versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology …","googleId":"C5docYF6XnQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312980","googleCitationCount":11,"googleAuthor":"J Souglakos"},{"title":"An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45","googleId":"AbplPkpSoYwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419360843","googleCitationCount":8,"googleAuthor":"F Cardoso"},{"title":"Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline …","googleId":"hWLeihe80qMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420397908","googleCitationCount":6,"googleAuthor":"D Dolling"},{"title":"Cognitive behavioral therapy or graded exercise therapy compared with usual care for severe fatigue in patients with advanced cancer during treatment: a …","googleId":"aqixsgI_sh0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354031","googleCitationCount":8,"googleAuthor":"WTA Van Der Graaf"},{"title":"Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001","googleId":"28wh4aQLRL0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30062-6/abstract","googleCitationCount":13,"googleAuthor":"RC Doebele"},{"title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"F85io6vBVUoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39898-7/abstract","googleCitationCount":30,"googleAuthor":"E Castro"},{"title":"LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal …","googleId":"lIt1mjYEfB4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39379-0/pdf","googleCitationCount":8,"googleAuthor":"A Grothey"},{"title":"Characterization of on-target adverse events caused by TRK inhibitor therapy","googleId":"IMp4OwIpN5UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398203","googleCitationCount":5,"googleAuthor":""},{"title":"ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee","googleId":"gC33zBCdAngJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399403","googleCitationCount":8,"googleAuthor":"PA Ascierto"},{"title":"Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III …","googleId":"X2tuCjW7ZykJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398999","googleCitationCount":5,"googleAuthor":"R Glynne-Jones"},{"title":"New hints towards a precision medicine strategy for IDH wild-type glioblastoma","googleId":"WRk3KBIrvfQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420424287","googleCitationCount":4,"googleAuthor":"BM Murphy"},{"title":"138O CNS metastases in HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan: DESTINY-Breast01 subgroup analyses","googleId":"ZK5O7LqaH-EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36318-3/abstract","googleCitationCount":14,"googleAuthor":""},{"title":"Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial","googleId":"uQKssSgFJl4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398331","googleCitationCount":9,"googleAuthor":"JA Di Palma"},{"title":"Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR …","googleId":"E4X5KINOBgcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354018","googleCitationCount":7,"googleAuthor":"M Saigi"},{"title":"A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia …","googleId":"sNkXhUwUOCUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420392966","googleCitationCount":9,"googleAuthor":"M Clemons"},{"title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the …","googleId":"LIavQYLN_vsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420424597","googleCitationCount":7,"googleAuthor":"U Dafni"},{"title":"Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results from a phase I/II trial","googleId":"68rXpXmeGXsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30419-3/abstract","googleCitationCount":14,"googleAuthor":""},{"title":"Financial toxicity in lung cancer: an assessment of magnitude, perception, and impact on quality of life","googleId":"GVryPl7ojioJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354122","googleCitationCount":8,"googleAuthor":"W Fu"},{"title":"Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy","googleId":"bYVAfJ7ElAsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310853","googleCitationCount":12,"googleAuthor":"J Vidal"},{"title":"Conversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine-or FOLFIRINOX-based induction chemotherapy (NEOLAP) …","googleId":"ljWYHnSvVyMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588913","googleCitationCount":13,"googleAuthor":""},{"title":"Activity of larotrectinib in TRK fusion lung cancer","googleId":"XIBRQdmZkL8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30060-2/abstract","googleCitationCount":12,"googleAuthor":"A Drilon"},{"title":"A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant …","googleId":"NTcg08-mTIIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360373","googleCitationCount":10,"googleAuthor":""},{"title":"Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a …","googleId":"d83tG3ZZQn4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)32591-6/abstract","googleCitationCount":11,"googleAuthor":"J Remon"},{"title":"The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer","googleId":"gCdulKRKST0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398690","googleCitationCount":5,"googleAuthor":"G Mauri"},{"title":"Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆","googleId":"J6RlTDboOUIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342039788X","googleCitationCount":5,"googleAuthor":""},{"title":"Durvalumab activity in previously treated patients who stopped durvalumab without disease progression","googleId":"ZDJIpcmjKtsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593875","googleCitationCount":7,"googleAuthor":"JC Soria"},{"title":"Long-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo+ ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets) …","googleId":"8pwtEE2GtV0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595229","googleCitationCount":10,"googleAuthor":"GV Long"},{"title":"Genomewide copy number alteration screening of circulating plasma DNA: potential for the detection of incipient tumors","googleId":"hmakyT2ThpwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309901","googleCitationCount":12,"googleAuthor":""},{"title":"Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma","googleId":"fSxC-lbZ3fYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420359470","googleCitationCount":5,"googleAuthor":""},{"title":"Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases","googleId":"1LpLr0Wqv9IJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398355","googleCitationCount":5,"googleAuthor":"O Metzger Filho"},{"title":"Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ …","googleId":"_IUT7LbfCD8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596922","googleCitationCount":8,"googleAuthor":""},{"title":"Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic …","googleId":"VF5Q4gDycQIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419360740","googleCitationCount":9,"googleAuthor":""},{"title":"On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2","googleId":"kB5DSvDfPcAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39892-6/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"NGS-based profiling reveals a critical contributing role of somatic D-loop mtDNA mutations in HBV-related hepatocarcinogenesis","googleId":"W6HxnPjeaW0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311998","googleCitationCount":8,"googleAuthor":""},{"title":"Prognostic significance of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) treated with immune …","googleId":"N0YY9E9vWZ0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30016-X/abstract","googleCitationCount":14,"googleAuthor":""},{"title":"First birth achieved after fertility preservation using vitrification of in vitro matured oocytes in a woman with breast cancer","googleId":"8f7oF_DdXqoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)35923-8/abstract","googleCitationCount":9,"googleAuthor":""},{"title":"LBA75 Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion)","googleId":"bOP91W2he0cJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7506419/","googleCitationCount":6,"googleAuthor":"FR Hirsch"},{"title":"Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study)","googleId":"SUZ9CGVFySsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586665","googleCitationCount":8,"googleAuthor":"A Drilon"},{"title":"KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden","googleId":"xtbxe2Q-DBcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420421702","googleCitationCount":4,"googleAuthor":"D Marinelli"},{"title":"Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts","googleId":"YVYtYKIrbOsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342036378X","googleCitationCount":6,"googleAuthor":"E Burkitt-Wright"},{"title":"Avoiding over-and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?","googleId":"tnCSfKiAFEYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312347","googleCitationCount":12,"googleAuthor":"A Matikas"},{"title":"Chemotherapy plus local-regional radiotherapy versus chemotherapy alone in primary metastatic nasopharyngeal carcinoma: A randomized, open-label, phase III trial","googleId":"rI-CjIc7UEoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)59320-6/abstract","googleCitationCount":9,"googleAuthor":""},{"title":"Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure","googleId":"91b7HY1ETPYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419532252","googleCitationCount":6,"googleAuthor":"M Alyamani"},{"title":"18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) …","googleId":"PRMOPP4n9DYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604321","googleCitationCount":8,"googleAuthor":"AM Menzies"},{"title":"Overall survival (OS) update in ALTER 1202: Anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC)","googleId":"IIGNdluRZEwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419598726","googleCitationCount":9,"googleAuthor":""},{"title":"Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)","googleId":"wI2O4utGDfcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959528X","googleCitationCount":8,"googleAuthor":"D Rischin"},{"title":"Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC)","googleId":"Jy3jJ8va4gMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419592079","googleCitationCount":8,"googleAuthor":"V Makker"},{"title":"Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models","googleId":"yA3kiA1zyioJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419390830","googleCitationCount":5,"googleAuthor":"H Jespersen"},{"title":"Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and …","googleId":"oV6uMfar37cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354055","googleCitationCount":7,"googleAuthor":""},{"title":"Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types","googleId":"vIN32Nud6uEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419360703","googleCitationCount":5,"googleAuthor":"V Ivaturi"},{"title":"Randomized phase II (RP2) study of ATR inhibitor M6620 in combination with gemcitabine versus gemcitabine alone in platinum-resistant high grade serous …","googleId":"QH2-VdfZMYsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604175","googleCitationCount":7,"googleAuthor":"PA Konstantinopoulos"},{"title":"Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer","googleId":"QHmAlpzWXncJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420364140","googleCitationCount":3,"googleAuthor":"S Dutta"},{"title":"Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: Pooled analysis of 6501 patients treated with fluorouracil …","googleId":"u1LOP2qmqCEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342035924X","googleCitationCount":5,"googleAuthor":"J Yin"},{"title":"Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer","googleId":"XU9SkaKn8nwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398902","googleCitationCount":5,"googleAuthor":"F Ruiz-Pace"},{"title":"Combinatorial immunotherapy strategies: most gods throw dice, but fate plays chess","googleId":"CxpwHk0n__EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)32593-X/abstract","googleCitationCount":7,"googleAuthor":"J Ciccolini"},{"title":"Associations of early life and adulthood adiposity with risk of epithelial ovarian cancer","googleId":"AyA8rab9h-YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310415","googleCitationCount":9,"googleAuthor":"T Huang"},{"title":"Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in checkmate 9KD","googleId":"6ZJbXrwKE1wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604059","googleCitationCount":6,"googleAuthor":""},{"title":"LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC)±atezolizumab (atezo) for …","googleId":"0EHi1GzH994J","googleLink":"https://www.researchgate.net/profile/Margarita_Donica/publication/345371639_LBA15_Primary_results_from_IMpassion131_a_double-blind_placebo-controlled_randomised_phase_III_trial_of_first-line_paclitaxel_PAC_atezolizumab_atezo_for_unresectable_locally_advancedmetastatic_triple-/links/5fd27161299bf188d40afe50/LBA15-Primary-results-from-IMpassion131-a-double-blind-placebo-controlled-randomised-phase-III-trial-of-first-line-paclitaxel-PAC-atezolizumab-atezo-for-unresectable-locally-advanced-metastatic-trip.pdf","googleCitationCount":6,"googleAuthor":"F André"},{"title":"Safety and efficacy of TRIplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) in patients (pts) with BRAF-mutated metastatic …","googleId":"hKdrcqMzaLcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595230","googleCitationCount":9,"googleAuthor":""},{"title":"Safety and efficacy of pembrolizumab (Pembro) monotherapy in elderly patients (Pts) with PD-L1–positive advanced NSCLC: pooled analysis from KEYNOTE-010 …","googleId":"ZLNLGxi6yekJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30052-3/abstract","googleCitationCount":12,"googleAuthor":"P Baas"},{"title":"Hyperprogression during immunotherapy: do we really want to know?","googleId":"ZmOi6P0b4ekJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31252-9/abstract","googleCitationCount":8,"googleAuthor":"S Champiat"},{"title":"Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma","googleId":"3_YgXegM5ekJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342036381X","googleCitationCount":5,"googleAuthor":"V Moreno"},{"title":"LBA45 First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study)","googleId":"kAcGkVgOBLYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42357-9/abstract","googleCitationCount":5,"googleAuthor":"PA Ascierto"},{"title":"Pembrolizumab in patients with MSI-H advanced endometrial cancer from the KEYNOTE-158 study","googleId":"uNP2m2WV8e8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419592572","googleCitationCount":6,"googleAuthor":""},{"title":"Niraparib therapy in patients with newly diagnosed advanced ovarian cancer (PRIMA/ENGOT-OV26/GOG-3012 study)","googleId":"QcO9t0yY9KkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604126","googleCitationCount":8,"googleAuthor":"IB Vergote"},{"title":"Primary results from TAIL, a global single-arm safety study of atezolizumab (atezo) monotherapy in a diverse population of patients with previously treated …","googleId":"axZKfNw5nEwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604424","googleCitationCount":7,"googleAuthor":"S Azevedo"},{"title":"Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase …","googleId":"I3igMxL0WfMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420432211","googleCitationCount":2,"googleAuthor":""},{"title":"Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab","googleId":"cMlfn6VU-ysJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419598751","googleCitationCount":6,"googleAuthor":"D Daniel"},{"title":"Benefit of prostate radiotherapy for patients with lymph node only or< 4 bone metastasis and no visceral metastases: Exploratory analyses of metastatic site …","googleId":"SpuphOViGsoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590664","googleCitationCount":8,"googleAuthor":"ND James"},{"title":"LBA17 ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with previously treated …","googleId":"6OIi3uM_3HcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42327-0/abstract","googleCitationCount":16,"googleAuthor":"K Punie"},{"title":"Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option","googleId":"GH5N_3OE6AoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311767","googleCitationCount":10,"googleAuthor":"SN Westin"},{"title":"NRG1 fusion-driven tumors: biology, detection and the therapeutic role of afatinib and other ErbB-targeting agents","googleId":"wFZhWfqIjIAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420424275","googleCitationCount":2,"googleAuthor":"K Tolba"},{"title":"Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 …","googleId":"XV2yr0JKKhsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341935402X","googleCitationCount":9,"googleAuthor":""},{"title":"Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase …","googleId":"2hoJ72fIdV8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311123","googleCitationCount":10,"googleAuthor":"S Delaloge"},{"title":"SO-26 Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients","googleId":"Zqj5W-2vcvcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39340-6/pdf","googleCitationCount":6,"googleAuthor":""},{"title":"LBA71 Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis","googleId":"EZWUlpk9zG4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42394-4/abstract","googleCitationCount":6,"googleAuthor":"A Desai"},{"title":"Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients …","googleId":"Mqc4-PyeEJkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30534-4/abstract","googleCitationCount":13,"googleAuthor":""},{"title":"LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab+ nab-paclitaxel vs placebo+ nab-paclitaxel in previously untreated …","googleId":"pGEc_Be6CZoJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506448/","googleCitationCount":7,"googleAuthor":"LA Emens"},{"title":"Phase (Ph) II study of MBG453+ spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy","googleId":"1iXmwrgh7_gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594145","googleCitationCount":7,"googleAuthor":"DW Kim"},{"title":"Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆","googleId":"IyIuWeNxY80J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420424615","googleCitationCount":4,"googleAuthor":"M Bandini"},{"title":"Molecular screening to select therapy for advanced cancer?","googleId":"7DkpRHL1apYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31172-X/abstract","googleCitationCount":11,"googleAuthor":"IF Tannock"},{"title":"A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer","googleId":"u31LmrWx5v0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312359","googleCitationCount":10,"googleAuthor":"RJ Kelly"},{"title":"Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)","googleId":"Fh_YjwOALCUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597368","googleCitationCount":7,"googleAuthor":"TM Kim"},{"title":"Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration …","googleId":"x-7m5RVTDDYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609762","googleCitationCount":6,"googleAuthor":"R Kurzrock"},{"title":"Impact of early introduction of steroid on immune-checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer treated","googleId":"eJ5hosmQbnQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344252","googleCitationCount":6,"googleAuthor":"A De Giglio"},{"title":"Updated overall survival (OS) from extended follow up in ARCHER 1050: a randomized Phase III study comparing dacomitinib with gefitinib as first-line …","googleId":"YN1Kh9RfAu4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582230","googleCitationCount":6,"googleAuthor":""},{"title":"Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial …","googleId":"BcY_nKhaYsAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419406996","googleCitationCount":9,"googleAuthor":""},{"title":"Validation of a clinicopathological and gene expression profile (CP-GEP) model for sentinel lymph node metastasis in primary cutaneous melanoma","googleId":"lckIDNYs8wgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595357","googleCitationCount":7,"googleAuthor":"D Tempel"},{"title":"Using methylation signatures on cell-free DNA for early cancer detection: a new era in liquid biopsy?","googleId":"3NGeYrZpslsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36411-5/pdf","googleCitationCount":4,"googleAuthor":""},{"title":"Management of toxicity to isoform α-specific PI3K inhibitors","googleId":"9TTVrHvfHxAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420343763","googleCitationCount":12,"googleAuthor":""},{"title":"Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK …","googleId":"i0zThZVYZvUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398379","googleCitationCount":2,"googleAuthor":""},{"title":"Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal …","googleId":"UlM1IW-p1Y4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419360764","googleCitationCount":7,"googleAuthor":""},{"title":"A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland","googleId":"v3_4HwlBkOgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420359287","googleCitationCount":4,"googleAuthor":""},{"title":"Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm …","googleId":"iZS6BqeHw0oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420424457","googleCitationCount":5,"googleAuthor":""},{"title":"Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network","googleId":"ovIZTPCnhxIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420422975","googleCitationCount":6,"googleAuthor":"B Bjerkehagen"},{"title":"610O Final overall survival (OS) analysis of PROfound: Olaparib vs physician's choice of enzalutamide or abiraterone in patients (pts) with metastatic castration …","googleId":"xKUe8dng_18J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40866-X/abstract","googleCitationCount":7,"googleAuthor":"JS De Bono"},{"title":"1670O Prospective data of first 1,797 hospitalised patients with cancer and COVID-19 derived from the COVID-19 Clinical Information Network and international …","googleId":"6nXSg6NqKoEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41731-4/abstract","googleCitationCount":5,"googleAuthor":"L Turtle"},{"title":"Comprehensive genomic profiling and clinical outcomes in patients (pts) with fibroblast growth factor receptor rearrangement-positive (FGFR2+) …","googleId":"aPKEGScWGv4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589372","googleCitationCount":5,"googleAuthor":"A Hollebecque"},{"title":"Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma …","googleId":"l6JJo1kXZW4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588974","googleCitationCount":7,"googleAuthor":"T Meyer"},{"title":"FOxTROT: An international randomised controlled trial in 1053 patients evaluating neoadjuvant chemotherapy (NAC) for colon cancer. On behalf of the …","googleId":"k_cjYQxhFnYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587440","googleCitationCount":5,"googleAuthor":"D Morton"},{"title":"Apalutamide (APA) and overall survival (OS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Updated results from the …","googleId":"isw9la_ioCYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590597","googleCitationCount":9,"googleAuthor":"MR Smith"},{"title":"Nivolumab versus chemotherapy in advanced esophageal squamous cell carcinoma (ESCC): the phase III ATTRACTION-3 study","googleId":"N0EdnZcrUSEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603881","googleCitationCount":7,"googleAuthor":"M Takahashi"},{"title":"Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and …","googleId":"gIQR-2j1Y6gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325588","googleCitationCount":10,"googleAuthor":"S Lonardi"},{"title":"LBA33 Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high‐grade ovarian carcinoma (HGOC): Final analysis …","googleId":"kq7OkdAsJe4J","googleLink":"https://www.clearityfoundation.org/wp-content/uploads/2020/10/PAOLA-ESMO-2020-PFS2-abstract.pdf","googleCitationCount":4,"googleAuthor":"F Heitz"},{"title":"Association between depth of response and overall survival: exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) …","googleId":"l9k_1iz6fEoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591633","googleCitationCount":5,"googleAuthor":"TK Choueiri"},{"title":"IMpower150: an exploratory analysis of efficacy outcomes in patients with EGFR mutations","googleId":"2yPh6yh2ulIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30053-5/abstract","googleCitationCount":11,"googleAuthor":"DWT Lim"},{"title":"Making immunotherapy 'cold'tumours 'hot'by chemotherapy-induced mutations—a misconception","googleId":"P2_ewO_wzVsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31089-0/abstract","googleCitationCount":9,"googleAuthor":"T Helleday"},{"title":"Circulating breast-derived DNA allows universal detection and monitoring of localized breast cancer","googleId":"l1i8PadHgp0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419417201","googleCitationCount":10,"googleAuthor":"J Moss"},{"title":"Updated overall survival (OS) and quality of life (QoL) in premenopausal patients (pts) with advanced breast cancer (ABC) who received ribociclib (RIB) or …","googleId":"The5kMy8YSkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585301","googleCitationCount":6,"googleAuthor":"MA Colleoni"},{"title":"INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II …","googleId":"VdNs2SrAoL8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419581819","googleCitationCount":7,"googleAuthor":"JCH Yang"},{"title":"A first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC","googleId":"46Bv31sYuJEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959127X","googleCitationCount":5,"googleAuthor":"E Jonasch"},{"title":"Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label …","googleId":"q1UetUI2wV8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420424627","googleCitationCount":2,"googleAuthor":"L Marandino"},{"title":"Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis","googleId":"c05vsIrp3r4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39819-7/abstract","googleCitationCount":5,"googleAuthor":"JO Prior"},{"title":"LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with …","googleId":"-v0Tk5oGjH0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39377-7/pdf","googleCitationCount":4,"googleAuthor":"B Sangro"},{"title":"First case of persistent pancytopenia associated with SARS-CoV-2 bone marrow infiltration in an immunocompromised patient","googleId":"tIxXVvHlttgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39926-9/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (NETs): results from the randomized …","googleId":"yR1dG1NTmbQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604333","googleCitationCount":7,"googleAuthor":""},{"title":"807O Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant (advanced or recurrent) ovarian cancer: Open-label …","googleId":"TRWintnmUhMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40942-1/abstract","googleCitationCount":6,"googleAuthor":"J Hamanishi"},{"title":"MONARCHplus: a phase III trial of abemaciclib plus nonsteroidal aromatase inhibitor (NSAI) or fulvestrant (F) for women with HR+/HER2-advanced breast …","googleId":"lkSmc2IP4c8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603741","googleCitationCount":6,"googleAuthor":""},{"title":"Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high …","googleId":"8DPJXcTZz80J","googleLink":"https://portal.findresearcher.sdu.dk/en/publications/health-related-quality-of-life-hrqol-in-patients-pts-treated-with","googleCitationCount":4,"googleAuthor":"T André"},{"title":"LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood …","googleId":"rphT06jAE5oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420345488","googleCitationCount":4,"googleAuthor":"RS Herbst"},{"title":"An enhanced prognostic score for overall survival of patients with cancer derived from a large real-world cohort","googleId":"TfnNe6HwQuwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399701","googleCitationCount":3,"googleAuthor":"T Becker"},{"title":"Choice of control tissue impacts designation of germline variants in a cohort of papillary thyroid carcinoma patients","googleId":"_e6JKDqnzZEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360749","googleCitationCount":3,"googleAuthor":"JC Rubinstein"},{"title":"Keynote-407 China extension study: pembrolizumab (pembro) plus chemotherapy in Chinese patients with metastatic squamous NSCLC","googleId":"Fe-OFza8cSYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582242","googleCitationCount":6,"googleAuthor":""},{"title":"Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, non-small cell lung cancer …","googleId":"6sYSgzh7bLMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344264","googleCitationCount":7,"googleAuthor":"A Drakaki"},{"title":"Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group","googleId":"iCJbfUNKaOAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398240","googleCitationCount":2,"googleAuthor":"M Vazquez"},{"title":"Nivolumab plus low-dose IPILIMUMAB as first-line treatment of advanced NSCLC: Overall survival analysis of checkmate 817","googleId":"ICPr6eSAdRUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344793","googleCitationCount":6,"googleAuthor":""},{"title":"Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer","googleId":"0vkxjvhVkyQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360385","googleCitationCount":4,"googleAuthor":"CH Barrios"},{"title":"Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers","googleId":"uxWyi4nJSngJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594224","googleCitationCount":5,"googleAuthor":""},{"title":"Redefining the IGCCCG classification in advanced non-seminoma","googleId":"snClG7sVDIwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591190","googleCitationCount":7,"googleAuthor":"G Daugaard"},{"title":"Bone health in childhood cancer: review of the literature and recommendations for the management of bone health in childhood cancer survivors","googleId":"EbBelKVZwlkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312086","googleCitationCount":8,"googleAuthor":""},{"title":"Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1","googleId":"B2CW9FEl4vAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36377-8/pdf","googleCitationCount":8,"googleAuthor":"M Khettab"},{"title":"Clonal haematopoiesis: a source of biological noise in cell-free DNA analyses","googleId":"aGs7bdOwwdwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31080-4/abstract","googleCitationCount":8,"googleAuthor":"C Abbosh"},{"title":"First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B","googleId":"ZCyxD4-GM8wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959161X","googleCitationCount":7,"googleAuthor":"RA Gafanov"},{"title":"Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumors: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001","googleId":"-tZuKFYzY_AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586987","googleCitationCount":5,"googleAuthor":"C Rolfo"},{"title":"First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A","googleId":"1lFDicpHL2sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591621","googleCitationCount":5,"googleAuthor":"JMG Larkin"},{"title":"Lurbinectedin as second-or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)","googleId":"-1v6hkpFctIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420359263","googleCitationCount":5,"googleAuthor":"M Pless"},{"title":"Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients","googleId":"bVK78XT20YIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419583338","googleCitationCount":6,"googleAuthor":""},{"title":"The immune profile of small HER2-positive breast cancers: A secondary analysis from the APT trial","googleId":"EVWrH3BmzFwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311287","googleCitationCount":7,"googleAuthor":"R Barroso-Sousa"},{"title":"LBA49 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial","googleId":"Dvs8Q7w8S3kJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42363-4/abstract","googleCitationCount":8,"googleAuthor":"C Faivre-Finn"},{"title":"Results of the TAPPAS trial: An adaptive enrichment phase III trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced …","googleId":"2VaILcEkmnwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419602899","googleCitationCount":6,"googleAuthor":"RL Jones"},{"title":"LBA86 Durvalumab (D)±tremelimumab (T)+ platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden …","googleId":"TM6Pc7WbER0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42419-6/abstract","googleCitationCount":3,"googleAuthor":"MC Garassino"},{"title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"GxLLSD4jr_0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42107-6/abstract","googleCitationCount":5,"googleAuthor":"M Fassnacht"},{"title":"Updated data of epitopes-HPV02 trial and external validation of efficacy of DCF in prospective epitopes-HPV01 study in advanced anal squamous cell …","googleId":"RkiRlFEsgJUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587555","googleCitationCount":5,"googleAuthor":"S Kim"},{"title":"Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics","googleId":"dpNkqauvhCoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31117-2/abstract","googleCitationCount":9,"googleAuthor":"H Hackl"},{"title":"Bevacizumab plus chemotherapy versus chemotherapy alone as first-line treatment for patients with RAS mutant unresectable colorectal liver-limited metastases: A …","googleId":"w0gnXY9HLy4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)60380-7/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Efficacy evaluation of concurrent nivolumab addition to a first-line, concurrent chemo-radiotherapy regimen in unresectable locally advanced NSCLC: Results …","googleId":"95YtTGz5SEgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959665X","googleCitationCount":7,"googleAuthor":"S Peters"},{"title":"Quantitative lymph node burden as a 'very-high-risk'factor identifying head and neck cancer patients benefiting from postoperative chemoradiation","googleId":"Q1WS5orRUmcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309949","googleCitationCount":8,"googleAuthor":"ZS Zumsteg"},{"title":"Oral THC: CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial","googleId":"jN_4phlgsKIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399968","googleCitationCount":4,"googleAuthor":"N Lintzeris"},{"title":"Efficacy of lung cancer screening appears to increase with prolonged intervention: results from the MILD trial and a meta-analysis","googleId":"3j03RdQHacEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31245-1/abstract","googleCitationCount":7,"googleAuthor":"M Rota"},{"title":"VELIA/GOG-3005: Integration of veliparib with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian …","googleId":"2ewGa1j8zuAJ","googleLink":"https://portal.findresearcher.sdu.dk/en/publications/veliagog-3005-integration-of-veliparib-with-front-line-chemothera","googleCitationCount":7,"googleAuthor":""},{"title":"Reproducibility and concordance of 4 clinically developed programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays in triple negative breast …","googleId":"K-dNdkkiFYYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585817","googleCitationCount":5,"googleAuthor":"C Denkert"},{"title":"711P Nivolumab+ ipilimumab (N+ I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and …","googleId":"aOAvqOoWvWwJ","googleLink":"https://www.researchgate.net/profile/Shruti_Saggi3/publication/345365652_711P_Nivolumab_ipilimumab_NI_vs_sunitinib_S_for_first-line_treatment_of_advanced_renal_cell_carcinoma_aRCC_in_CheckMate_214_4-year_follow-up_and_subgroup_analysis_of_patients_pts_without_nephrectomy/links/5fd7f6ad299bf140880f5a58/711P-Nivolumab-ipilimumab-N-I-vs-sunitinib-S-for-first-line-treatment-of-advanced-renal-cell-carcinoma-aRCC-in-CheckMate-214-4-year-follow-up-and-subgroup-analysis-of-patients-pts-without-nephrectom.pdf","googleCitationCount":5,"googleAuthor":""},{"title":"LBA70_PR The impact of COVID-19 on oncology professionals: Initial results of the ESMO resilience task force survey collaboration","googleId":"fQ1BwQoC3VMJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506393/","googleCitationCount":2,"googleAuthor":"S Banerjee"},{"title":"Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2 …","googleId":"EEfgpRzu7cUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959696X","googleCitationCount":6,"googleAuthor":"S Siena"},{"title":"Inducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results …","googleId":"YMmdJZltyYkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593310","googleCitationCount":7,"googleAuthor":"D Rischin"},{"title":"Pembrolizumab vs chemotherapy in patients with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second …","googleId":"EABTlbOmLvcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589761","googleCitationCount":5,"googleAuthor":""},{"title":"A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL","googleId":"QE0S46-Aj7UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589669","googleCitationCount":7,"googleAuthor":"DJ Pinato"},{"title":"Chemotherapy in localized soft tissue sarcoma: will we soon have to treat grade 1 tumors? Update on CINSARC performances","googleId":"cIUIuJvEg3UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30982-2/abstract","googleCitationCount":8,"googleAuthor":"T Valentin"},{"title":"Cancer mortality and predictions for 2018 in selected Australasian countries and Russia","googleId":"dvPl-t3kVGYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309937","googleCitationCount":5,"googleAuthor":"M Malvezzi"},{"title":"Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: a multicenter open label phase II trial (NVALT19)","googleId":"_LTLTO-_LPQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604527","googleCitationCount":5,"googleAuthor":"R Cornelissen"},{"title":"Comparison of patient populations identified by different PD-L1 assays in in triple-negative breast cancer (TNBC)","googleId":"uG702wmLxQkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30282-0/abstract","googleCitationCount":11,"googleAuthor":""},{"title":"Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis of a …","googleId":"OoQCIphKtwsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604278","googleCitationCount":5,"googleAuthor":""},{"title":"Height as a mediator of sex differences in cancer risk","googleId":"ksLu85g_VUQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360579","googleCitationCount":1,"googleAuthor":"BC Fu"},{"title":"Anti-PD1 treatment of advanced melanoma: development of criteria for a safe stop","googleId":"Emp4rT3XMzQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31251-7/abstract","googleCitationCount":5,"googleAuthor":"AMM Eggermont"},{"title":"Phase I study of gefitinib (G)+ durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR …","googleId":"wj4LaT7SnicJ","googleLink":"https://mdanderson.elsevierpure.com/en/publications/phase-i-study-of-gefitinib-g-durvalumab-d-for-locally-advancedmet","googleCitationCount":6,"googleAuthor":"SW Kim"},{"title":"Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the 1st-and 2nd-line treatment of unresectable mCRC","googleId":"MYOX_PG4AKsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30960-3/abstract","googleCitationCount":7,"googleAuthor":"S Lonardi"},{"title":"Treatment-free survival, with and without toxicity, as a novel outcome applied to immuno-oncology agents in advanced renal cell carcinoma","googleId":"JmMefyRg44YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591840","googleCitationCount":4,"googleAuthor":"MM Regan"},{"title":"Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumours","googleId":"8DHg7aJj4n4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594157","googleCitationCount":4,"googleAuthor":"C Massard"},{"title":"Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications","googleId":"eoj7gEV92hMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589384","googleCitationCount":4,"googleAuthor":""},{"title":"Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion)","googleId":"DUSRbOqE4pcJ","googleLink":"https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/covidwho-804086","googleCitationCount":3,"googleAuthor":""},{"title":"Safety and Efficacy of Quavonlimab, a Novel Anti–CTLA-4 Antibody (MK-1308), in Combination with Pembrolizumab in First-Line Advanced Non–Small Cell …","googleId":"EMt4b0AZKioJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420431758","googleCitationCount":1,"googleAuthor":"J Bar"},{"title":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and …","googleId":"btiWx0H14-kJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39949-X/abstract","googleCitationCount":3,"googleAuthor":"JP Machiels"},{"title":"Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from …","googleId":"hSYq1dqDOMAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399300","googleCitationCount":17,"googleAuthor":"F Montemurro"},{"title":"Docetaxel for hormone-naïve prostate cancer (PCa): Results from long-term follow-up of non-metastatic (M0) patients in the STAMPEDE randomised trial","googleId":"46_DHhXzPr0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590688","googleCitationCount":4,"googleAuthor":"ND James"},{"title":"Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma","googleId":"qfBg97Wo8Q8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419600323","googleCitationCount":4,"googleAuthor":"C Borg"},{"title":"A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma","googleId":"NBQeKINiMXQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459899","googleCitationCount":4,"googleAuthor":""},{"title":"The FDA approval of pembrolizumab for patients with TMB> 10 mut/Mb: was it a wise decision? No","googleId":"5auEc2zWw9YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534%2820%2939935-X/fulltext","googleCitationCount":5,"googleAuthor":"V Prasad"},{"title":"A multi-center phase IIA trial to assess the safety and efficacy of BL-8040 (a CXCR4 inhibitor) in combination with pembrolizumab and chemotherapy in …","googleId":"WxMK8lvpk1MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344781","googleCitationCount":5,"googleAuthor":"M Hidalgo"},{"title":"Activity of EGFR antibody in non-V600 BRAF mutant metastatic colorectal cancer","googleId":"CTBYx5KxG54J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30991-3/abstract","googleCitationCount":8,"googleAuthor":"Y Wang"},{"title":"HER2: Defining a Neu target in non-small-cell lung cancer","googleId":"qxVMKBjHj2EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31096-8/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"HSD3B1 (1245A> C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide …","googleId":"5sMQNP-womEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398938","googleCitationCount":3,"googleAuthor":""},{"title":"VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian …","googleId":"lpARJ9VcD0kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960414X","googleCitationCount":5,"googleAuthor":"E Swisher"},{"title":"Sperm count in Swedish clinical stage I testicular cancer patients following adjuvant treatment","googleId":"kanofeyHxO4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311135","googleCitationCount":5,"googleAuthor":""},{"title":"First report of AURORA, the Breast International Group (BIG) molecular screening initiative for metastatic breast cancer (MBC) patients (pts)","googleId":"6wd0BT809esJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30420-X/abstract","googleCitationCount":6,"googleAuthor":"F Hilbers"},{"title":"TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) …","googleId":"7qknh2GRQdEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420420617","googleCitationCount":3,"googleAuthor":"R Jankowitz"},{"title":"Efficacy and safety of nintedanib+ docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated …","googleId":"xu0f8S430HYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597125","googleCitationCount":6,"googleAuthor":"S Haas"},{"title":"Androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus …","googleId":"1GV9Brp-_yAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590998","googleCitationCount":5,"googleAuthor":"KN Chi"},{"title":"Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on …","googleId":"IJmeWtf8n5UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309895","googleCitationCount":6,"googleAuthor":"A Matikas"},{"title":"Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy …","googleId":"9Lx0s8HabOQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30262-5/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Effect of second-line cabozantinib on health states for patients with advanced hepatocellular carcinoma (aHCC) after sorafenib: QTWiST analysis from the …","googleId":"_2RJZjMbiYsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589700","googleCitationCount":4,"googleAuthor":""},{"title":"Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 study","googleId":"22cY5a_u7iwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604291","googleCitationCount":4,"googleAuthor":""},{"title":"Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally …","googleId":"sgwxApH68sUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310786","googleCitationCount":6,"googleAuthor":"K Hutcheson"},{"title":"Early detection of pancreatic ductal adenocarcinoma using methylation signatures in circulating tumour DNA","googleId":"mUSHNspINhkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589049","googleCitationCount":4,"googleAuthor":""},{"title":"Exaggeration of PFS by blinded, independent, central review (BICR)","googleId":"OrG4tubPNTsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310269","googleCitationCount":6,"googleAuthor":"V Gebski"},{"title":"Double-blind randomized phase II results comparing concurrent high-dose cisplatin chemorradiation (CRT) plus debio 1143 or placebo in high-risk patients …","googleId":"cOXfWgY_1T0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604229","googleCitationCount":4,"googleAuthor":""},{"title":"Frequency and clinicopathological characteristics of biliary tract carcinomas harboring the FGFR2-fusion gene: a prospective observational study (PRELUDE …","googleId":"ac0K3DdcUUcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589402","googleCitationCount":5,"googleAuthor":"A Naganuma"},{"title":"Outcomes based on Albumin‐Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular …","googleId":"NL7MyRiTDTIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30530-7/abstract","googleCitationCount":5,"googleAuthor":"R Miksad"},{"title":"Prognostic impact of the use of antibiotics in patients with advanced non-small cell lung cancer (NSCLC) receiving PD-(L) 1 targeting monoclonal antibodies","googleId":"rk7Uk4nTELAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30106-1/abstract","googleCitationCount":8,"googleAuthor":"LA Mauti"},{"title":"The potential influence of human Y-chromosome haplogroup on COVID-19 prevalence and mortality","googleId":"AMtRNMqPWowJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42104-0/abstract","googleCitationCount":4,"googleAuthor":""},{"title":"Phase Ib, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumours","googleId":"fxCno9y9_nQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594364","googleCitationCount":3,"googleAuthor":""},{"title":"Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2","googleId":"OShqCjpI3AEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603777","googleCitationCount":5,"googleAuthor":"RC Doebele"},{"title":"Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240","googleId":"MqbuC3LLxu0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30535-6/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"High-risk neuroblastoma: where do we go?","googleId":"rivzS4g5HZ0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)53226-4/abstract","googleCitationCount":3,"googleAuthor":""},{"title":"A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) …","googleId":"ZqggrHkLv20J","googleLink":"https://vbn.aau.dk/en/publications/a-randomised-double-blind-placebo-controlled-phase-ii-trial-of-pa","googleCitationCount":2,"googleAuthor":"MR Mirza"},{"title":"Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA","googleId":"-Gqh8RNS8v0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604436","googleCitationCount":4,"googleAuthor":"N Peled"},{"title":"T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants","googleId":"rg4aRYHymYIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312050","googleCitationCount":4,"googleAuthor":"TP Mourikis"},{"title":"Breaking avelumab resistance with combined ipilimumab and nivolumab in metastatic Merkel cell carcinoma?","googleId":"ZzWJpOxPQq4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)60974-9/abstract","googleCitationCount":4,"googleAuthor":"M Goebeler"},{"title":"BAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib combination given with continuous or intermittent schedule in patients with …","googleId":"EoK116VmAIQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604151","googleCitationCount":5,"googleAuthor":"N Colombo"},{"title":"Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study","googleId":"Ke1NtfewcV0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311639","googleCitationCount":8,"googleAuthor":""},{"title":"IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)","googleId":"QS1ZZ_zaKpIJ","googleLink":"https://elibrary.ru/item.asp?id=43977890","googleCitationCount":3,"googleAuthor":"JS de Bono"},{"title":"Pexidartinib (Pex) for locally advanced tenosynovial giant cell tumour (TGCT): characterization of hepatic adverse reactions (ARs)","googleId":"qsIQCAhT4lwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603182","googleCitationCount":3,"googleAuthor":"H Gelderblom"},{"title":"Phase II study of pembrolizumab with enzalutamide (Enz) in metastatic, castration-resistant prostate cancer (mCRPC): 30 patient expansion with examination …","googleId":"PknI-lUseN8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590640","googleCitationCount":4,"googleAuthor":"JN Graff"},{"title":"Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small …","googleId":"ofX1tZ97urAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419580383","googleCitationCount":3,"googleAuthor":"V Subbiah"},{"title":"POD1UM-202: phase II study of retifanlimab in patients (pts) with squamous carcinoma of the anal canal (SCAC) who progressed following platinum-based …","googleId":"OpsBNuMSgF4J","googleLink":"https://portal.findresearcher.sdu.dk/en/publications/pod1um-202-phase-ii-study-of-retifanlimab-in-patients-pts-with-sq","googleCitationCount":2,"googleAuthor":"D Gilbert"},{"title":"CHLOROBRAIN phase IB trial: The addition of chloroquine, an autophagy inhibitor, to concurrent radiation and temozolomide for newly diagnosed …","googleId":"KbMqFzUSgjQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586471","googleCitationCount":4,"googleAuthor":"I Compter"},{"title":"Genomic characteristics and predicted ancestry of NTRK1/2/3 and ROS1 fusion-positive tumours from> 165,000 pan-solid tumours","googleId":"c1ST_xKjQ24J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586653","googleCitationCount":4,"googleAuthor":""},{"title":"Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of …","googleId":"wa8O-X7nfCUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420397945","googleCitationCount":1,"googleAuthor":""},{"title":"Prognostic and predictive impact of high tumor mutation burden (TMB) in solid tumors: A systematic review and meta-analysis","googleId":"bvqTgtGDQVIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419583211","googleCitationCount":3,"googleAuthor":""},{"title":"Alpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase III RESORCE trial","googleId":"ksZUTftglUAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589712","googleCitationCount":5,"googleAuthor":""},{"title":"On the right TRK: from oncogene discovery to cancer therapeutics","googleId":"KewhpccVYiYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)55115-8/abstract","googleCitationCount":3,"googleAuthor":"M Barbacid"},{"title":"Unintended on-target chromosomal instability following CRISPR/Cas9 single gene targeting","googleId":"9Q3W2gWG6YAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39799-4/fulltext","googleCitationCount":3,"googleAuthor":"J Przewrocka"},{"title":"Benefit of immunotherapy (IT) in advanced non-small cell lung cancer (NSCLC) in elderly patients (EP)","googleId":"moTCul8Dd6YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30118-8/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Results of the phase II TRAXAR study: A randomized phase II trial of axitinib and TRC105 (TRAX) versus axitinib (AX) alone in patients with advanced or …","googleId":"3EFTLs8XT2AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591281","googleCitationCount":3,"googleAuthor":"TK Choueiri"},{"title":"A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells","googleId":"YQuQ0fI90WUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594388","googleCitationCount":5,"googleAuthor":""},{"title":"Radiomics to predict response to immunotherapy, bridging the gap from proof of concept to clinical applicability?","googleId":"MZjlnOnzhZQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31212-8/abstract","googleCitationCount":4,"googleAuthor":"N Paragios"},{"title":"Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with …","googleId":"E6Vk8Gjv91YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593462","googleCitationCount":4,"googleAuthor":""},{"title":"Prospective, multicenter registry trial to evaluate the clinical feasibility of targeted axillary dissection (TAD) in patients (pts) with breast cancer (BC) and core …","googleId":"-X1aZfiz550J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419584034","googleCitationCount":4,"googleAuthor":"M Reinisch"},{"title":"Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus …","googleId":"1N9RO0A0CC4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311688","googleCitationCount":10,"googleAuthor":""},{"title":"Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors","googleId":"AU74g6Q3CxIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360543","googleCitationCount":2,"googleAuthor":"JC Soria"},{"title":"Preliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer …","googleId":"fSY7723lzXIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590652","googleCitationCount":5,"googleAuthor":"JR Osborne"},{"title":"Novel polyurea/polyurethane nanocapsules loaded with a tambjamine analog to improve cancer chemotherapy delivery and safety in lung cancer","googleId":"hW8cYuGDlp0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960089X","googleCitationCount":3,"googleAuthor":"A Arias"},{"title":"Safety of thoracic radiotherapy in patients with prior immune-related adverse events from immune checkpoint inhibitors","googleId":"NpLNUrSU99cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420424664","googleCitationCount":1,"googleAuthor":"N Shaverdian"},{"title":"Dissociated responses in patients with metastatic solid tumours treated with immunotherapy","googleId":"frcdHFz2Zz4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594935","googleCitationCount":4,"googleAuthor":"X Paoletti"},{"title":"Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC)","googleId":"yJASw6h6rkIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596673","googleCitationCount":4,"googleAuthor":"J Naidoo"},{"title":"TiNivo: tivozanib combined with nivolumab results in prolonged progression free survival in patients with metastatic renal cell carcinoma (mRCC): final results","googleId":"IN2ZAma8EnMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591608","googleCitationCount":4,"googleAuthor":"S Negrier"},{"title":"Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study …","googleId":"qggBJD9a4wwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312852","googleCitationCount":5,"googleAuthor":""},{"title":"High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: First results of the AcSé pembrolizumab study","googleId":"3e62PtuMWVoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594820","googleCitationCount":3,"googleAuthor":"JY Blay"},{"title":"Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: a multicenter study","googleId":"4RgfXXB91GsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344343","googleCitationCount":3,"googleAuthor":"A Cortellini"},{"title":"Response to WC Taylor, and C. Fiala and EP Diamandis","googleId":"9_bm5usvF2sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39895-1/abstract","googleCitationCount":2,"googleAuthor":"MC Liu"},{"title":"Phase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)","googleId":"wa-NvtqVoAgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30018-3/abstract","googleCitationCount":8,"googleAuthor":"A Hollebecque"},{"title":"Efficacy and safety of first-line durvalumab (D)±tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m …","googleId":"b8LcIsIcr9wJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30261-3/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Therapeutic drug monitoring of oral anticancer drugs-preliminary results of a prospective study","googleId":"W5k8d2UdlDQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586641","googleCitationCount":3,"googleAuthor":""},{"title":"Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast …","googleId":"3bfWBaA1ZLQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399348","googleCitationCount":1,"googleAuthor":"SJ Luen"},{"title":"Patients and physicians' satisfaction with telemedicine (TM) in cancer care and factors that correlate with a positive patient's experience","googleId":"n5PdAVekb4sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419599239","googleCitationCount":4,"googleAuthor":"T Abbas"},{"title":"A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer","googleId":"o40t9GGSxQ4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341936082X","googleCitationCount":5,"googleAuthor":"F Saad"},{"title":"ZEBRA: an ACCRU/IRCI multicenter phase 2 study of pembrolizumab in patients with advanced small bowel adenocarcinoma (SBA)","googleId":"AOWi8m4UCv8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30515-0/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma …","googleId":"HLmNZ2rYVtwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341955116X","googleCitationCount":5,"googleAuthor":""},{"title":"INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with …","googleId":"JRvuNa6PKCMJ","googleLink":"https://portal.findresearcher.sdu.dk/en/publications/inovatyon-study-randomized-phase-iii-international-study-comparin","googleCitationCount":3,"googleAuthor":"N Colombo"},{"title":"1581O Estimation of European cancer burden for the year 2020","googleId":"QPFKKZvC4ZoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42388-9/abstract","googleCitationCount":1,"googleAuthor":"G Randi"},{"title":"Phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell …","googleId":"uPWZfFwn83gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593991","googleCitationCount":4,"googleAuthor":"V Makker"},{"title":"IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib plus nivolumab in advanced soft tissue and bone …","googleId":"xi2eNKKHCE8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419602917","googleCitationCount":3,"googleAuthor":""},{"title":"Analysis of tumour samples from SOLO1: frequency of BRCA specific loss of heterozygosity (LOH) and progression-free survival (PFS) according to …","googleId":"KkrDcw230UEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419592110","googleCitationCount":3,"googleAuthor":"C Gourley"},{"title":"Quality of life of metastatic urothelial cancer (mUC) patients treated with enfortumab vedotin (EV) following platinum-containing chemotherapy and a …","googleId":"AMOF66wjPykJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591372","googleCitationCount":3,"googleAuthor":""},{"title":"Impact of germline mutations in homologous recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer …","googleId":"oWQibnv50MYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590925","googleCitationCount":3,"googleAuthor":"E Castro"},{"title":"Novel treatment options in the management of metastatic castration-naïve prostate cancer; which treatment modality to choose?","googleId":"tTPSvydvdLIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609683","googleCitationCount":4,"googleAuthor":""},{"title":"Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): integrated analysis of ALKA-372-001, STARTRK-1 and …","googleId":"MhlCcH1Dj0cJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30058-4/abstract","googleCitationCount":5,"googleAuthor":"A Drilon"},{"title":"Tepotinib plus gefitinib in patients with MET-amplified EGFR-mutant NSCLC: long-term outcomes of the INSIGHT study","googleId":"SHUxNIw4yZ4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419581236","googleCitationCount":3,"googleAuthor":"DW Kim"},{"title":"Excellent CBR and prolonged PFS in non-squamous NSCLC with oral CA-170, an inhibitor of VISTA and PD-L1","googleId":"8H7rRIsg6pwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594212","googleCitationCount":5,"googleAuthor":"S Gupta"},{"title":"A phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous …","googleId":"GHZFoxBDHvgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597721","googleCitationCount":3,"googleAuthor":"I Bondarenko"},{"title":"611O Abiraterone acetate plus prednisolone for hormone-naïve prostate cancer (PCa): Long-term results from metastatic (M1) patients in the STAMPEDE randomised …","googleId":"onqsdk_zovkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40867-1/abstract","googleCitationCount":2,"googleAuthor":"N James"},{"title":"Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV-negative oropharyngeal cancer","googleId":"a0838eudHKIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593334","googleCitationCount":4,"googleAuthor":"V Noronha"},{"title":"Brigatinib in ALK TKI-pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC): the use via expanded access to brigatinib (UVEA-Brig) study","googleId":"VVgT55uDczAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597526","googleCitationCount":3,"googleAuthor":""},{"title":"746P EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD …","googleId":"f1ZtrVyNfxEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40814-2/abstract","googleCitationCount":2,"googleAuthor":""},{"title":"Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on …","googleId":"_tkom3OgKyYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419599719","googleCitationCount":3,"googleAuthor":"G Zalcman"},{"title":"LBA18 Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP)+ fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth …","googleId":"yNQmpMwzDnQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42328-2/abstract","googleCitationCount":5,"googleAuthor":"F André"},{"title":"Personalized treatment according to geriatric assessment in first-line recurrent and/or metastatic (R/M) head and neck squamous cell cancer (HNSCC) …","googleId":"dYyiaYjvhP0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959322X","googleCitationCount":3,"googleAuthor":"J Guigay"},{"title":"1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with …","googleId":"ema9cK71UC4J","googleLink":"https://www.researchgate.net/profile/Manfred_Welslau2/publication/345365307_1421MO_Final_results_and_subgroup_analysis_of_the_PETRARCA_randomized_phase_II_AIO_trial_Perioperative_trastuzumab_and_pertuzumab_in_combination_with_FLOT_versus_FLOT_alone_for_HER2_positive_resectabl/links/5ff454db92851c13feebb30e/1421MO-Final-results-and-subgroup-analysis-of-the-PETRARCA-randomized-phase-II-AIO-trial-Perioperative-trastuzumab-and-pertuzumab-in-combination-with-FLOT-versus-FLOT-alone-for-HER2-positive-resectabl.pdf","googleCitationCount":2,"googleAuthor":"SE Al-Batran"},{"title":"Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase …","googleId":"jA5w4dxJwEUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310221","googleCitationCount":5,"googleAuthor":"D Schadendorf"},{"title":"First report of efficacy and safety from a phase II trial of tislelizumab, an anti-PD-1 antibody, for the treatment of PD-L1+ locally advanced or metastatic …","googleId":"1pcTlI0Rld8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591360","googleCitationCount":7,"googleAuthor":""},{"title":"Disparities in access to oncology clinical trials in Europe in the period 2009-2019","googleId":"GfvWIbZZlTcJ","googleLink":"https://orbi.uliege.be/handle/2268/253768","googleCitationCount":2,"googleAuthor":"M Scheffler"},{"title":"Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in elderly patients: A subgroup analysis from TOSCA trial","googleId":"Rb9APBwvGqwJ","googleLink":"https://www.researchgate.net/profile/Gerardo_Rosati/publication/344414424_399O_Oxaliplatin_plus_fluoropyrimidines_as_adjuvant_therapy_for_colon_cancer_in_elderly_patients_A_subgroup_analysis_from_TOSCA_trial/links/5f730c5f92851c14bc9d0b0c/399O-Oxaliplatin-plus-fluoropyrimidines-as-adjuvant-therapy-for-colon-cancer-in-elderly-patients-A-subgroup-analysis-from-TOSCA-trial.pdf","googleCitationCount":2,"googleAuthor":"S Lonardi"},{"title":"Sex-based differences of the tumor mutational burden and T-cell inflammation of the tumor microenvironment","googleId":"lIDini_Z_jQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31120-2/abstract","googleCitationCount":6,"googleAuthor":"F Conforti"},{"title":"Divining responder populations from survival data","googleId":"DxPLrBUZ-2AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311962","googleCitationCount":4,"googleAuthor":"S Ventz"},{"title":"Applicability of the Lung Immune Prognostic Index (LIPI) in patients with metastatic solid tumors when treated with Immune Checkpoint Inhibitors (ICI) in early clinical …","googleId":"PvfSsvT5LKYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30013-4/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"Vitamin B6 catabolism and lung cancer risk: results from the Lung Cancer Cohort Consortium (LC3)","googleId":"-sGV04b9ZXQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310828","googleCitationCount":3,"googleAuthor":"H Zuo"},{"title":"Update on the phase II SUMMIT trial: Neratinib+ fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer","googleId":"mFPiGnNqjqkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30302-3/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous …","googleId":"C4yv7hcD0rYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582126","googleCitationCount":3,"googleAuthor":"SK Sandhu"},{"title":"Pharmacokinetics (PK), safety, and efficacy of trastuzumab deruxtecan with OATP1B/CYP3A inhibitors in subjects with HER2-expressing advanced …","googleId":"xuL_iwInvN8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585520","googleCitationCount":3,"googleAuthor":""},{"title":"Comparison of real-world response rate (rwRR) to RECIST-based response rate in patients with advanced non-small cell lung cancer (aNSCLC)","googleId":"B_B8s3LvPd0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597885","googleCitationCount":4,"googleAuthor":"AB Bourla"},{"title":"BGB-A333, an anti-PD-L1 monoclonal antibody, in combination with tislelizumab in patients with urothelial carcinoma","googleId":"OtEn42R-2PMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40645-3/abstract","googleCitationCount":2,"googleAuthor":"V Moreno"},{"title":"Efficacy and safety of isatuximab plus pomalidomide and dexamethasone in East Asian patients with relapsed/refractory multiple myeloma: A subgroup …","googleId":"UKhFf-qiTuUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419579431","googleCitationCount":3,"googleAuthor":"MC Wang"},{"title":"Combination of intratumoural double-stranded RNA (dsRNA) BO-112 with systemic anti-PD-1 in patients with anti-PD-1 refractory cancer","googleId":"4h7XLnw8nw0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344872","googleCitationCount":2,"googleAuthor":"I Marquez-Rodas"},{"title":"Recent eUpdate to the ESMO Clinical Practice Guidelines on early and locally advanced non-small-cell lung cancer (NSCLC)","googleId":"dPfXRf0XN6IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39865-3/pdf","googleCitationCount":1,"googleAuthor":"G Pentheroudakis"},{"title":"O-6 The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced …","googleId":"1JZSKItw8z0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39358-3/pdf","googleCitationCount":2,"googleAuthor":""},{"title":"Efficacy and safety of nintedanib+ docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated …","googleId":"3ydErE3j5G4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344446","googleCitationCount":3,"googleAuthor":""},{"title":"861P Limited implementation of the ESMO-ESGO (European Society of Gynaecological Oncology)-ESTRO (European Society for Radiotherapy and Oncology) …","googleId":"DQjMiB7syhcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40996-2/abstract","googleCitationCount":1,"googleAuthor":"N Colombo"},{"title":"Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III …","googleId":"Sy5NDsMVpmQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420393133","googleCitationCount":2,"googleAuthor":"M Van der Meulen"},{"title":"FUSAFE individual patient data meta-analysis (MA) to assess the performance of dihydropyrimidine dehydrogenase (DPD) gene polymorphisms for predicting …","googleId":"T3_2w3N17WAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587890","googleCitationCount":3,"googleAuthor":""},{"title":"Anlotinib for advanced hepatocellular carcinoma: Interim results from the phase II ALTER0802 study","googleId":"R5-UvHVZPAQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589670","googleCitationCount":3,"googleAuthor":""},{"title":"IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo)+ …","googleId":"dP8XbDbw4OwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30152-8/abstract","googleCitationCount":5,"googleAuthor":"S Peters"},{"title":"100,000 genomes project: Integrating whole genome sequencing (WGS) data into clinical practice","googleId":"pd3owMfB99AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419619010","googleCitationCount":2,"googleAuthor":"J Mitchell"},{"title":"O-3 Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis of three clinical trials (STARTRK-2 …","googleId":"2o_TzVK1LlMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39355-8/pdf","googleCitationCount":2,"googleAuthor":"S Siena"},{"title":"Phase II trial of HER2-PET/CT using 68Ga-anti-HER2 VHH1 for characterization of HER2 presence in brain metastases of breast cancer patients","googleId":"D5iOGmfxCc4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30353-9/abstract","googleCitationCount":4,"googleAuthor":"M Keyaerts"},{"title":"The role of plasma microseminoprotein-beta in prostate cancer: an observational nested case–control and Mendelian randomization study in the European …","googleId":"dfJBOzJqmk4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312098","googleCitationCount":4,"googleAuthor":"KS Byrne"},{"title":"Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD …","googleId":"I-4f5XrMMysJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595679","googleCitationCount":2,"googleAuthor":"SK Sandhu"},{"title":"Durable anti-tumor activity of the multi-targeted inhibitor lenvatinib in patients with advanced or metastatic thymic carcinoma: Preliminary results from a …","googleId":"JsffEb0BREgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419599744","googleCitationCount":4,"googleAuthor":""},{"title":"A novel bispecific BCMAxCD3 T cell-engaging antibody that treat multiple myeloma (MM) with minimal cytokine secretion","googleId":"qBPIrrCb_7AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419601468","googleCitationCount":3,"googleAuthor":""},{"title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO …","googleId":"E-bxMnWwjMQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420359299","googleCitationCount":4,"googleAuthor":"E Senkus-Konefka"},{"title":"LBA11 IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab+ chemotherapy in early triple-negative breast cancer (TNBC)","googleId":"LpSzIDhlyR4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42321-X/abstract","googleCitationCount":3,"googleAuthor":"CH Barrios"},{"title":"Multiple-cohort analysis investigating FGFR3 alteration as a predictor of non-response to neoadjuvant pembrolizumab (pembro) in muscle-invasive bladder …","googleId":"iYGyAXl2PrIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591219","googleCitationCount":5,"googleAuthor":"A Briganti"},{"title":"Passion for immune checkpoint blockade in triple negative breast cancer: comment on the IMpassion130 study","googleId":"kBjNBT-v-bEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30988-3/abstract","googleCitationCount":6,"googleAuthor":"S Loi"},{"title":"Survival outcomes in stage IV small-cell lung cancer (IV-SCLC): Analysis from SEER database","googleId":"fr0HUE5jnSwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344628","googleCitationCount":2,"googleAuthor":"MD Gomez"},{"title":"Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy: Pooled analysis based on the GBG …","googleId":"DDv6qX5H1fMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30376-X/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"A phase I study of ATR inhibitor, AZD6738, as monotherapy in advanced solid tumours (PATRIOT part A, B)","googleId":"vbexyfXAgH4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586720","googleCitationCount":5,"googleAuthor":"M Dillon"},{"title":"Durvalumab+ monalizumab, mFOLFOX6, and bevacizumab in patients (pts) with metastatic microsatellite-stable colorectal cancer (MSS-CRC)","googleId":"Bjk8T9XWrfQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594133","googleCitationCount":3,"googleAuthor":"M Cho"},{"title":"METEOR-1: a phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours","googleId":"MM784Tc0Lj8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586604","googleCitationCount":6,"googleAuthor":"LL Siu"},{"title":"PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy","googleId":"PrZYxMYAA_YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30186-3/abstract","googleCitationCount":4,"googleAuthor":""},{"title":"LBA65 The Canadian Cancer Trials Group PA. 7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P …","googleId":"7sahSUxK7gUJ","googleLink":"https://www.researchgate.net/profile/Duan_Tu2/publication/345371394_LBA65_The_Canadian_Cancer_Trials_Group_PA7_trial_Results_of_a_randomized_phase_II_study_of_gemcitabine_GEM_and_nab-paclitaxel_Nab-P_vs_GEM_nab-P_durvalumab_D_and_tremelimumab_T_as_first_line_therapy_i/links/5ffbd5a5299bf14088886586/LBA65-The-Canadian-Cancer-Trials-Group-PA7-trial-Results-of-a-randomized-phase-II-study-of-gemcitabine-GEM-and-nab-paclitaxel-Nab-P-vs-GEM-nab-P-durvalumab-D-and-tremelimumab-T-as-first-line-therapy.pdf","googleCitationCount":2,"googleAuthor":"DJ Renouf"},{"title":"Comparison of immuno-oncology (IO) biomarkers in adenocarcinoma (ACB), urothelial carcinoma (UCB) and squamous cell carcinoma (SCCB) of the bladder …","googleId":"C-1XEyHC5q0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591463","googleCitationCount":3,"googleAuthor":"AB Schrock"},{"title":"Alpelisib (ALP)+ fulvestrant (FUL) for patients with hormone receptor–positive (HR+), HER2− advanced breast cancer (ABC): Management and time course of …","googleId":"oQppqByNKqsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585465","googleCitationCount":3,"googleAuthor":"F André"},{"title":"Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting","googleId":"WulZALHnYxgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30992-5/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"Prospective testing of circulating tumour DNA in metastatic breast cancer facilitates clinical trial enrollment and precision oncology","googleId":"v_dRr6l4kF4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419583363","googleCitationCount":2,"googleAuthor":""},{"title":"BRCA1/2 testing in HER2-advanced breast cancer (ABC): Results from the European component of a multi-country real-world study","googleId":"qbeJhOLnt5MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585143","googleCitationCount":3,"googleAuthor":""},{"title":"NRG1-fusion positive gastrointestinal tumours: afatinib as a novel potential treatment option","googleId":"ZYYytu1qVxkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30807-5/abstract","googleCitationCount":3,"googleAuthor":"B Weinberg"},{"title":"Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours","googleId":"DZin-WFLbh0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586690","googleCitationCount":3,"googleAuthor":"AR Parikh"},{"title":"Phase I dose escalation study of a selective androgen receptor modulator RAD140 in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer …","googleId":"XrBCZADY8pYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585659","googleCitationCount":2,"googleAuthor":""},{"title":"O-4 NTRK gene fusions in bilio-pancreatic cancers","googleId":"jpa8tI09ZSgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39356-X/pdf","googleCitationCount":2,"googleAuthor":""},{"title":"A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours","googleId":"y8iEV3ILn1oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590585","googleCitationCount":3,"googleAuthor":"A Drilon"},{"title":"Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials?","googleId":"AQk2kGntoj0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325886","googleCitationCount":4,"googleAuthor":""},{"title":"Outcome and mutational landscape of patients with PIK3CA-mutated metastatic breast cancer (mBC)","googleId":"gtkC0EYeKYIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30417-X/abstract","googleCitationCount":4,"googleAuthor":"A Lusque"},{"title":"New designs in early clinical drug development","googleId":"FfIjyVlSDqMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341945984X","googleCitationCount":2,"googleAuthor":"A Mansinho"},{"title":"Prognostic value of tumour infiltrating lymphocytes (TILs) in patients with early-stage triple negative breast cancers (TNBC) in the absence of chemotherapy","googleId":"tuUrEWciQPIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419584010","googleCitationCount":3,"googleAuthor":"G Bataillon"},{"title":"Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall …","googleId":"2ZDUJiGd-XEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420421556","googleCitationCount":6,"googleAuthor":""},{"title":"Real life use of talimogene laherparepvec in melanoma in centers in Austria and Switzerland","googleId":"WZAmoDRAzPkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595539","googleCitationCount":2,"googleAuthor":"C Hoeller"},{"title":"Mixture-cure modeling for resected stage III/IV melanoma in the phase III CheckMate 238 trial","googleId":"SW9v8XEooG4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595412","googleCitationCount":2,"googleAuthor":"M Kurt"},{"title":"Phase I evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced …","googleId":"77WKt7vB2NQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594182","googleCitationCount":2,"googleAuthor":""},{"title":"Exposure-response analyses of ALK-inhibitors crizotinib and alectinib in NSCLC patients","googleId":"KYiN-WlIBF4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596946","googleCitationCount":2,"googleAuthor":"JM Janssen"},{"title":"Phase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic …","googleId":"3qpqT2NenAgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586628","googleCitationCount":6,"googleAuthor":"A Naing"},{"title":"Pharmacokinetic (PK) assessment of BT1718: A phase I/II a study of BT1718, a first in class bicycle toxin conjugate (BTC), in patients (pts) with advanced solid …","googleId":"D8Qm5dbghikJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586860","googleCitationCount":2,"googleAuthor":"J Evans"},{"title":"A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence …","googleId":"rPMFejUfIfkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30705-7/abstract","googleCitationCount":3,"googleAuthor":"J Knox"},{"title":"1688P Outcome of older cancer patients infected with COVID-19 at Gustave Roussy Cancer Center","googleId":"UDbt7KJmrIcJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506356/","googleCitationCount":1,"googleAuthor":""},{"title":"Intracranial and extracranial efficacy of lorlatinib in the post second-generation ALK tyrosine kinase inhibitor (TKI) setting","googleId":"tGhrxE_2C8kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596958","googleCitationCount":2,"googleAuthor":""},{"title":"Predictive modeling in colorectal cancer: time to move beyond consensus molecular subtypes","googleId":"m7demNaXHzYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)32604-1/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Post-hoc analyses of a subgroup of patients with advanced biliary tract cancer (BTC) who crossed over to treatment with etoposide toniribate (EDO-S7. 1) in a …","googleId":"afD_1o2WMEkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589414","googleCitationCount":3,"googleAuthor":"S Kasper"},{"title":"WGS implementation in standard cancer diagnostics for every cancer patient (WIDE)","googleId":"02qI_6dBvKAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959617X","googleCitationCount":2,"googleAuthor":"L Bosch"},{"title":"LBA50 ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non …","googleId":"aTmp9NJ8vX4J","googleLink":"https://www.researchgate.net/profile/Delvys_Rodriguez-Abreu/publication/345365073_LBA51_KEYNOTE-024_5-year_OS_update_First-line_1L_pembrolizumab_pembro_vs_platinum-based_chemotherapy_chemo_in_patients_pts_with_metastatic_NSCLC_and_PD-L1_tumour_proportion_score_TPS_50/links/5fe9ed4292851c13fecfa64a/LBA51-KEYNOTE-024-5-year-OS-update-First-line-1L-pembrolizumab-pembro-vs-platinum-based-chemotherapy-chemo-in-patients-pts-with-metastatic-NSCLC-and-PD-L1-tumour-proportion-score-TPS-50.pdf","googleCitationCount":2,"googleAuthor":""},{"title":"Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated …","googleId":"hgOrPzbIFEIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586744","googleCitationCount":2,"googleAuthor":"M Voskoboynik"},{"title":"Phase I Clinical Study for Validation of Fimaporfin-Based Photochemical Internalisation: A Novel Technology for Enhancing Cellular Immune Responses …","googleId":"qA9jNlWbkyYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344963","googleCitationCount":2,"googleAuthor":""},{"title":"Phase II multicenter open label study of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study)","googleId":"ffZwBxGmT6QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960428X","googleCitationCount":2,"googleAuthor":"H Jespersen"},{"title":"LBA74 Disparities in cancer during the COVID-19 pandemic: COVID-19 and cancer outcomes study (CCOS)","googleId":"1nHwoT-ld-MJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506490/","googleCitationCount":1,"googleAuthor":"D Doroshow"},{"title":"Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option","googleId":"Dx12fVzxsFoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419600967","googleCitationCount":3,"googleAuthor":"K Tolba"},{"title":"LBA72 Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium …","googleId":"Jgu3FxhZB0gJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506465/","googleCitationCount":2,"googleAuthor":"J Warner"},{"title":"Phase I combination dose-finding/phase II expansion cohorts of lenvatinib+ etoposide+ ifosfamide in patients (pts) aged 2 to≤ 25 years with relapsed …","googleId":"dNKjQ3iilMQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960298X","googleCitationCount":2,"googleAuthor":"R Venkatramani"},{"title":"Assessing the clinical relevance of drug-drug interactions (DDI) with darolutamide (DARO)","googleId":"YI_MIgnKgNYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591062","googleCitationCount":2,"googleAuthor":""},{"title":"Comprehensive genomic profiling (CGP) of carcinoma of unknown primary origin (CUP): Retrospective molecular classification of potentially eligible patients …","googleId":"lcZoy9TOIo0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604540","googleCitationCount":4,"googleAuthor":"L Mileshkin"},{"title":"Pre-specified pilot analysis of a randomised pilot/phase II/III trial comparing standard dose vs dose-escalated concurrent chemoradiotherapy (CRT) in anal …","googleId":"9D9lBdM51P4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587567","googleCitationCount":4,"googleAuthor":"J Webster"},{"title":"The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with first-line nab-paclitaxel and gemcitabine: post-hoc analysis of an …","googleId":"ElEXkI3qIx4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30802-6/abstract","googleCitationCount":4,"googleAuthor":"J Riedl"},{"title":"Meta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer","googleId":"SUE2pIt70EsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419584666","googleCitationCount":2,"googleAuthor":""},{"title":"Single cycle induction treatment with cisplatin/docetaxel plus durvalumab/tremelimumab in stage III-IVB head and neck squamous cell cancer (CheckRad …","googleId":"NErDi8rtr6cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959336X","googleCitationCount":2,"googleAuthor":"M Eckstein"},{"title":"Safety and feasibility of extending flushing interval every 3 months for maintenance of TICVPS in CRC patients after completion of curative intended treatments","googleId":"D8yiNVBk3bsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)58092-9/abstract","googleCitationCount":3,"googleAuthor":""},{"title":"Safety and efficacy of the oral CXCR4 inhibitor X4P-001+ axitinib in advanced renal cell carcinoma patients: an analysis of subgroup responses by prior …","googleId":"Y1Ehd4Qtk8oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959398X","googleCitationCount":2,"googleAuthor":""},{"title":"Gastric cancer in young Latin women: bad prognostic factors and outcomes","googleId":"B9eRc92XZUYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30664-7/abstract","googleCitationCount":4,"googleAuthor":"M Herrera"},{"title":"Osimertinib in epidermal growth factor receptor (EGFR) T790M advanced non-small cell lung cancer (NSCLC): Analysis of patients with central nervous …","googleId":"HRQjPB3zpxYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597289","googleCitationCount":2,"googleAuthor":"G Metro"},{"title":"Association between PIK3CA mutation status and development of brain metastases in HR+/HER2-metastatic breast cancer","googleId":"ex88wTlvvGMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585404","googleCitationCount":2,"googleAuthor":""},{"title":"Inconsistencies in currently used definitions of sarcopenia in oncology","googleId":"9btYyxZDs9sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)36077-6/abstract","googleCitationCount":2,"googleAuthor":""},{"title":"Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with …","googleId":"RoSwjtc3YZsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30626-X/abstract","googleCitationCount":5,"googleAuthor":"P Hammel"},{"title":"Phase II study of cetuximab rechallenge in patients with RAS wild-type metastatic colorectal cancer: E-Rechallenge trial","googleId":"FlutAU2M_2oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)62207-6/abstract","googleCitationCount":3,"googleAuthor":""},{"title":"Correlation of various clinical, imaging and laboratory parameters with outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune …","googleId":"24OcWWMgBTkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30115-2/abstract","googleCitationCount":5,"googleAuthor":"K Rounis"},{"title":"Interpreting the impact of apalutamide on overall survival among patients with non-metastatic castration-resistant prostate cancer","googleId":"Pu7Dv8snPvcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43226-2/abstract","googleCitationCount":2,"googleAuthor":"ZR McCaw"},{"title":"An international randomized cross-over bio-equivalence study of oral paclitaxel+ HM30181 compared with weekly intravenous (IV) paclitaxel in patients with …","googleId":"tVq3UvRtUpwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586999","googleCitationCount":2,"googleAuthor":"C Jackson"},{"title":"Revisiting surveillance schemes for cancer survivors","googleId":"mIWaWB4rZ44J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31201-3/abstract","googleCitationCount":3,"googleAuthor":"Ø Holme"},{"title":"Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma","googleId":"uigtFEVq2q4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312748","googleCitationCount":4,"googleAuthor":""},{"title":"SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)","googleId":"D1-ZHc_ZHFgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604308","googleCitationCount":2,"googleAuthor":"S Danson"},{"title":"NY-ESO-1 and LAGE1A: An emerging target for cell therapies in solid tumours","googleId":"Jt8-Npq6L1gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594418","googleCitationCount":2,"googleAuthor":""},{"title":"Initial results of a phase II study of nivolumab and ipilimumab in metastatic adrenal tumours","googleId":"RJhAO-HorzcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591992","googleCitationCount":2,"googleAuthor":"MA Habra"},{"title":"Not only gene mutation matters: Development of flow cytometry panel to determine BRCA2 deficiency for personalised therapy by PARP inhibitors in …","googleId":"hEOyUqqtvVoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419619587","googleCitationCount":2,"googleAuthor":""},{"title":"A phase II study of monalizumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I1 cohort …","googleId":"1obQciRoQDYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593218","googleCitationCount":3,"googleAuthor":""},{"title":"Phase I clinical trial of PD-1 knockout anti-MUC1 CAR-T cells in the treatment of patients with non-small cell lung cancer","googleId":"gJE29fDVmmgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344148","googleCitationCount":2,"googleAuthor":"E McGowan"},{"title":"Pembrolizumab (pembro) plus mFOLFOX or FOLFIRI in patients with metastatic colorectal cancer (mCRC): KEYNOTE-651 cohorts B and D","googleId":"kEnW5m7b9aMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588287","googleCitationCount":2,"googleAuthor":"M Fakih"},{"title":"Harmonization study of tumour mutational burden determination in non-small cell lung cancer (NSCLC)","googleId":"LWzbjhWKsyQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603625","googleCitationCount":2,"googleAuthor":""},{"title":"Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial","googleId":"67N87ZRmiaIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459863","googleCitationCount":3,"googleAuthor":"EM Holmes"},{"title":"A Phase III study of TAS-118 plus oxaliplatin versus S-1 plus cisplatin as first-line chemotherapy in patients with advanced gastric cancer (SOLAR study)","googleId":"_qT-tXoBBbIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30957-3/abstract","googleCitationCount":4,"googleAuthor":""},{"title":"EMERGE: Epigenetic modulation of the immune response in gastrointestinal cancers","googleId":"LfnoKY2R69kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588901","googleCitationCount":2,"googleAuthor":""},{"title":"A Phase Ib study of oraxol in combination with ramucirumab in patients with gastric or esophageal cancers who failed previous chemotherapy","googleId":"e7SVTZpTMk0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590160","googleCitationCount":2,"googleAuthor":""},{"title":"Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single agent or in combination with chemotherapy in …","googleId":"pyKjmBDf3xgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420343969","googleCitationCount":2,"googleAuthor":""},{"title":"A case treated with Crizotinib after secondary MET amplification of a double rare L747S and G719S EGFR mutation pulmonary sarcomatoid carcinoma","googleId":"y3r_y9oSAGMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)35942-1/abstract","googleCitationCount":2,"googleAuthor":""},{"title":"Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?","googleId":"NB8Hi1GuwtUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31250-5/abstract","googleCitationCount":3,"googleAuthor":""},{"title":"Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA","googleId":"ad5a_MrcssIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582217","googleCitationCount":3,"googleAuthor":""},{"title":"Androgen deprivation therapy may constitute a more effective COVID-19 prophylactic than therapeutic strategy","googleId":"LA6rI0swtecJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42103-9/abstract","googleCitationCount":2,"googleAuthor":"IM Bennani-Baiti"},{"title":"Phase i/ii study with cxcl12 inhibitor nox-a12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer","googleId":"f1NLCQtfecsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588330","googleCitationCount":2,"googleAuthor":""},{"title":"1916P Larotrectinib treatment of advanced TRK fusion thyroid cancer","googleId":"JD7DrLjBn8MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41400-0/abstract","googleCitationCount":3,"googleAuthor":"A Drilon"},{"title":"Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer …","googleId":"NtLBNKXgZ6UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30955-X/abstract","googleCitationCount":3,"googleAuthor":"P Hammel"},{"title":"Phase I study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 …","googleId":"2kUiw_nlLiYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594327","googleCitationCount":2,"googleAuthor":"JJ Luke"},{"title":"Immune activation with a novel immune switch anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in phase I/II first-in-human MATINS trial in patients …","googleId":"jYGxuKR16nsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603789","googleCitationCount":2,"googleAuthor":"P Bono"},{"title":"Randomised efficacy and safety results for atezolizumab (Atezo)+ bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular …","googleId":"4xLbTARyipwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582114","googleCitationCount":2,"googleAuthor":""},{"title":"Impact of digital patient monitoring (DPM) on quality of clinical care of cancer immunotherapy (CIT)-treated patients (pts) with advanced/metastatic non-small …","googleId":"Lo2Empmm3LIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342034463X","googleCitationCount":2,"googleAuthor":"C Jacob"},{"title":"Analysis of efficacy outcomes based on programmed death ligand 1 (PD-L1) scoring techniques in patients with head and neck squamous cell carcinoma …","googleId":"jt_ciYIBIWcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593279","googleCitationCount":2,"googleAuthor":"E Cohen"},{"title":"Cancer immunotherapy with STING agonist and PD-1 immune checkpoint inhibitor effectively suppresses peritoneal carcinomatosis of colon cancer","googleId":"e4WPTloFnGUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30650-7/abstract","googleCitationCount":4,"googleAuthor":"C Kim"},{"title":"A single-arm, open-label, multicenter, phase IIIb clinical trial with nivolumab in subjects with recurrent or metastatic platinum-refractory squamous cell …","googleId":"7DB2nfYUFLcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593528","googleCitationCount":2,"googleAuthor":"MC Merlano"},{"title":"1294P RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: Outcomes by EGFR mutation type","googleId":"mIsXPR15CTYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41604-7/abstract","googleCitationCount":2,"googleAuthor":"E Nadal"},{"title":"Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB)","googleId":"H7qFJpIuA94J","googleLink":"https://portal.findresearcher.sdu.dk/en/publications/tucatinib-vs-placebo-added-to-trastuzumab-and-capecitabine-in-pre","googleCitationCount":1,"googleAuthor":"S Loi"},{"title":"Homozygous HSD3B1 (1245C) inheritance and poor outcomes in metastatic castration-resistant prostate cancer with abiraterone or enzalutamide: what does it mean …","googleId":"nA72TrqVfTIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39896-3/abstract","googleCitationCount":2,"googleAuthor":"N Sharifi"},{"title":"First-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumours","googleId":"NBUe0qPYAdoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586781","googleCitationCount":2,"googleAuthor":""},{"title":"Phase II study of DHP107 oral paclitaxel in first-line, HER2 negative recurrent/metastatic breast cancer (OPTIMAL study, NCT03315364)","googleId":"v3vmDg4a2jQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585684","googleCitationCount":2,"googleAuthor":""},{"title":"PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC","googleId":"QY7AZBRV7b8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582035","googleCitationCount":2,"googleAuthor":""},{"title":"Nab-paclitaxel (Nab) plus gemcitabine (G) is more effective than G alone in locally advanced, unresectable pancreatic cancer (LAUPC): The GAP trial, a …","googleId":"4siBliACusoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588925","googleCitationCount":2,"googleAuthor":"S Cascinu"},{"title":"Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+ chemotherapy (CT) as neoadjuvant treatment (NAT) for triple …","googleId":"D2YnAkBP9dEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30276-5/abstract","googleCitationCount":4,"googleAuthor":"S Loi"},{"title":"1676MO Prevalence and clinical impact of asymptomatic or mildly symptomatic SARSCoV-2 infection among actively treated cancer patients during COVID-19 …","googleId":"AI38wiGVXOsJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7506461/","googleCitationCount":1,"googleAuthor":""},{"title":"Phase II monotherapy efficacy of cancer metabolism targeting SM-88 in heavily pre-treated PDAC patients","googleId":"gm6dYt9myO4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589360","googleCitationCount":3,"googleAuthor":""},{"title":"Efficiency of controlled cryotherapy in prevention of chemotherapy induced peripheral neuropathy (CIPN)","googleId":"wTtQBxEakAgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419599343","googleCitationCount":2,"googleAuthor":""},{"title":"Tepotinib in NSCLC patients with METex14 mutations: interim results from the phase II VISION study","googleId":"tXHXunOKD9AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419621745","googleCitationCount":3,"googleAuthor":"J Mazieres"},{"title":"Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor-mutated …","googleId":"uAuosOTlk2cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597290","googleCitationCount":2,"googleAuthor":"SP Nagar"},{"title":"Final results of phase II trial (MIRACULUM) of the novel PD-1 inhibitor prolgolimab in patients with advanced melanoma","googleId":"CY6u8HvTEhMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420345051","googleCitationCount":3,"googleAuthor":""},{"title":"Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm …","googleId":"fCa6o1I8_hYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603819","googleCitationCount":4,"googleAuthor":"A Grothey"},{"title":"1410P Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC","googleId":"jGq6KQxpLx8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41720-X/abstract","googleCitationCount":2,"googleAuthor":"A Nagrial"},{"title":"The ImmunoTOX multidisciplinary board: A descriptive study of collaborative management of immune-related adverse events","googleId":"hOgZijI-dfgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419598891","googleCitationCount":2,"googleAuthor":"JM Michot"},{"title":"RASA1 loss in a BRAF-mutated Langerhans cell sarcoma: a mechanism of resistance to BRAF inhibitor","googleId":"HoJIEUcsR9YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31233-5/abstract","googleCitationCount":3,"googleAuthor":"F Jouenne"},{"title":"Androgen deprivation and SARS-CoV-2 in men with prostate cancer","googleId":"fWeuxuYYrWYJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323668/","googleCitationCount":2,"googleAuthor":"M Koskinen"},{"title":"Development and validation of a risk model integrating plasma Epstein-Barr virus DNA (EBV DNA) level and TNM stage for stratification of nasopharyngeal …","googleId":"cYq55jv6cTsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419579601","googleCitationCount":2,"googleAuthor":"BBY Ma"},{"title":"Response of nivolumab monotherapy in 124 Japanese patients with advanced melanoma: interim analysis of prospective observational study (CREATIVE …","googleId":"louUt74M-ysJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341957990X","googleCitationCount":2,"googleAuthor":""},{"title":"A phase II study of trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or-mutated advanced non-small cell lung cancer","googleId":"5yPVK7GH5egJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30132-2/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical …","googleId":"0DGABh4XKK4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420421714","googleCitationCount":2,"googleAuthor":""},{"title":"An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic …","googleId":"rhCYcC3cfbIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30509-5/abstract","googleCitationCount":4,"googleAuthor":"M Reni"},{"title":"Buparlisib (BKM120) in refractory head and neck squamous cell carcinoma harbouring or not a PI3KCA mutation: A phase II multicenter trial","googleId":"zLpEFL-CsTEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593322","googleCitationCount":4,"googleAuthor":""},{"title":"A meta-analysis of efficacy and safety of cetuximab with biweekly vs. weekly dosing","googleId":"QaM3tlOhPAAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40562-9/abstract","googleCitationCount":1,"googleAuthor":"A Parikh"},{"title":"Predictive and prognostic value of B-cell gene-expression signatures and B-cell receptor (BCR) repertoire in HER2+ breast cancer: A correlative analysis of …","googleId":"PDHCFlrKjn0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419584009","googleCitationCount":3,"googleAuthor":"JS Parker"},{"title":"Evaluation of pathological complete response as a trial-level surrogate for long-term survival outcomes among triple-negative breast cancer patients receiving …","googleId":"xFvnvNHIew4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30378-3/abstract","googleCitationCount":4,"googleAuthor":""},{"title":"PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors","googleId":"KdtwSYSXS5YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419600025","googleCitationCount":2,"googleAuthor":"B Pellegrino"},{"title":"Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as the second-line treatment in patients with advanced gastric cancer","googleId":"EL75b4wb0gwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30945-7/abstract","googleCitationCount":3,"googleAuthor":""},{"title":"Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial","googleId":"aS4oO7lBsqIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419578796","googleCitationCount":2,"googleAuthor":""},{"title":"685P A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer …","googleId":"c2htdNIdOQgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42076-9/abstract","googleCitationCount":2,"googleAuthor":""},{"title":"Immunogenicity and optimal timing of 13-valent pneumococcal conjugate vaccination during adjuvant chemotherapy in gastric and colorectal cancer: a …","googleId":"J2ABQE-6r_UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419599562","googleCitationCount":3,"googleAuthor":"W Choi"},{"title":"TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease …","googleId":"3VJRYijmLokJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582060","googleCitationCount":2,"googleAuthor":"H Yu"},{"title":"LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours","googleId":"AfUTAaXE7fAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42353-1/abstract","googleCitationCount":2,"googleAuthor":"Z Lwin"},{"title":"Important considerations prior to elimination of breast cancer surgery after neoadjuvant systemic therapy: Listening to what our patients want","googleId":"jd_s87TWJ-0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39307-8/abstract","googleCitationCount":2,"googleAuthor":""},{"title":"1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC","googleId":"b939U1-GnKgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41710-7/abstract","googleCitationCount":2,"googleAuthor":"DW Kim"},{"title":"Impact of adjuvant trastuzumab emtansine (T-DM1) on incidence of metastatic breast cancer (mBC): An epidemiological model of patients with HER2-positive …","googleId":"YruXwnOts50J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419584198","googleCitationCount":2,"googleAuthor":""},{"title":"Making adjuvant therapy decisions with uncertain data","googleId":"Iu7s_aK0S5IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31093-2/abstract","googleCitationCount":4,"googleAuthor":"B Gyawali"},{"title":"Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from …","googleId":"rK2GK2fBgYQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589694","googleCitationCount":2,"googleAuthor":"PR Galle"},{"title":"Efficacy of weekly paclitaxel-bevacizumab combination in advanced non squamous non-small cell lung cancer (NSCLC): a retrospective multicentric study","googleId":"kPve2_AhyTMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597745","googleCitationCount":3,"googleAuthor":""},{"title":"Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic …","googleId":"yl34LOkGaDwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419578097","googleCitationCount":2,"googleAuthor":"S Nakamori"},{"title":"External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung …","googleId":"nCESRACd8y0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594741","googleCitationCount":2,"googleAuthor":"JM Riedl"},{"title":"Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): results from the phase II …","googleId":"XPTk6jg5xqIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586124","googleCitationCount":2,"googleAuthor":"DW Kim"},{"title":"A phase I study of XZP-3287, a novel oral CDK4/6 Inhibitor, administered on a continuous dosing schedule, in patients with advanced solid tumours","googleId":"R6XvKv7w69sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585660","googleCitationCount":2,"googleAuthor":""},{"title":"A phase Ia/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumours","googleId":"d6q3u8tfYYwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586823","googleCitationCount":2,"googleAuthor":""},{"title":"Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 …","googleId":"dBARTukM_5wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419579066","googleCitationCount":3,"googleAuthor":""},{"title":"CANOPY phase III program: Three studies evaluating canakinumab in patients with non-small cell lung cancer (NSCLC)","googleId":"o7qdLJTA-PYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597940","googleCitationCount":2,"googleAuthor":""},{"title":"Efficacy and safety of first-line durvalumab (D)±tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC","googleId":"dw4y7ELbNuIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419581820","googleCitationCount":2,"googleAuthor":"KH Lee"},{"title":"Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: An update of the phase III KATHERINE trial of post …","googleId":"5vHVrvAxEYMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603650","googleCitationCount":6,"googleAuthor":"C Huang"},{"title":"Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours","googleId":"yBMiiQjgbm4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586756","googleCitationCount":4,"googleAuthor":"F Meric-Bernstam"},{"title":"1675MO Screening of COVID-19 disease based on chest CT and PCR for cancer patients undergoing radiotherapy in a French coronavirus hotspot","googleId":"bCf50oQfxm4J","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506406/","googleCitationCount":1,"googleAuthor":"R Sun"},{"title":"Afatinib in EGFR TKI-naïve patients (pts) with locally advanced/metastatic NSCLC harbouring EGFR mutations: an interim analysis of a phase IIIB trial","googleId":"todCCo1_l5IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30064-X/abstract","googleCitationCount":3,"googleAuthor":""},{"title":"Personalized cancer supportive care in COVID-19 era","googleId":"xCatCs0USeYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39817-3/pdf","googleCitationCount":2,"googleAuthor":"GH Lyman"},{"title":"Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small-cell lung cancer","googleId":"ISCb3cBe54YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31129-9/abstract","googleCitationCount":4,"googleAuthor":"H Reis"},{"title":"Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma","googleId":"PNkhgBKrIdAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341958190X","googleCitationCount":2,"googleAuthor":"SH Tan"},{"title":"P-342 Margetuximab combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013)+/-chemotherapy in first-line therapy of advanced/metastatic HER2+ …","googleId":"iIoVroCLPRQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39723-4/pdf","googleCitationCount":1,"googleAuthor":"D Catenacci"},{"title":"Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: the AURA LM study","googleId":"FU8-tSIevcQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30054-7/abstract","googleCitationCount":3,"googleAuthor":""},{"title":"FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line …","googleId":"GOGOFPbOMe4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30617-9/abstract","googleCitationCount":3,"googleAuthor":"NM Lago"},{"title":"Successful pregnancy in a cancer patient previously cured of a gestational trophoblastic tumor by immunotherapy","googleId":"jL-uesfRr6YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36076-2/pdf","googleCitationCount":2,"googleAuthor":"PA Bolze"},{"title":"3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early …","googleId":"oVlrd_Ab0HQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419584162","googleCitationCount":2,"googleAuthor":"J Stebbing"},{"title":"EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer","googleId":"VHtqWSAlVF0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587257","googleCitationCount":2,"googleAuthor":""},{"title":"1736P Elevated AXL expression following SARS-CoV-2 infection in non-small cell lung cancer","googleId":"rmAOvs9ZKqYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41796-X/abstract","googleCitationCount":1,"googleAuthor":""},{"title":"Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study","googleId":"Tsu3sX5eSsYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398665","googleCitationCount":3,"googleAuthor":""},{"title":"Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases","googleId":"KgiU8DlZtzIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40469-7/abstract","googleCitationCount":1,"googleAuthor":"M Fakih"},{"title":"1731P Molecular diagnostics for cancer patients and high-risk individuals during the SARS-CoV-2 pandemic at the Institute for Oncology and Radiology of Serbia","googleId":"rCzAkN1XBz8J","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506399/","googleCitationCount":1,"googleAuthor":""},{"title":"LBA47 Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to …","googleId":"5aUqOdWE4MsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42359-2/abstract","googleCitationCount":1,"googleAuthor":"AJ Stratigos"},{"title":"Facilitating access to new therapeutic options through clinical trials: the vision of a regulator to reconcile innovation and safety","googleId":"Gwz6taFR2CEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)32597-7/abstract","googleCitationCount":3,"googleAuthor":""},{"title":"Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated …","googleId":"NS34qDYlvgAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591335","googleCitationCount":2,"googleAuthor":""},{"title":"Ramucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure-response analysis","googleId":"naVJ4qFrV54J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589748","googleCitationCount":2,"googleAuthor":"J Llovet"},{"title":"Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): subgroup analysis of the SAUL study in locally advanced …","googleId":"PRxBhRqxQckJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591384","googleCitationCount":2,"googleAuthor":"Y Loriot"},{"title":"Early-phase clinical drug development of novel agents: a changing paradigm","googleId":"ONY8k1TXc-wJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31249-9/abstract","googleCitationCount":2,"googleAuthor":"E Calvo"},{"title":"Integrated safety analysis of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with ovarian cancer in the treatment and …","googleId":"CMbRgxvaWm4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419592158","googleCitationCount":2,"googleAuthor":"C Aghajanian"},{"title":"Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group","googleId":"XscrBF8ltDgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341953229X","googleCitationCount":7,"googleAuthor":"T André"},{"title":"LBA77 Anti-SARS-CoV-2 antibody response in patients with cancer and oncology healthcare workers: A multicenter, prospective study","googleId":"K8jhajoEZD8J","googleLink":"https://www.researchgate.net/profile/Antonio_Marra2/publication/345371398_LBA77_Anti-SARS-CoV-2_antibody_response_in_patients_with_cancer_and_oncology_healthcare_workers_A_multicenter_prospective_study/links/5faa9f42299bf15bae0638e6/LBA77-Anti-SARS-CoV-2-antibody-response-in-patients-with-cancer-and-oncology-healthcare-workers-A-multicenter-prospective-study.pdf","googleCitationCount":1,"googleAuthor":"A Marra"},{"title":"Prevalence and prognostic effect of high tumor mutation burden (TMB-H) across multiple less common solid cancers using a real-world dataset","googleId":"5IbZrRpOqzIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419600062","googleCitationCount":3,"googleAuthor":""},{"title":"Phase II study of neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0) cutaneous squamous cell carcinoma of the head and neck (CSCC …","googleId":"HhvvRV3UX04J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960431X","googleCitationCount":3,"googleAuthor":"P Nagarajan"},{"title":"Efficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemo in patients with NSCLC","googleId":"YGj1j2ZWDW8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597836","googleCitationCount":2,"googleAuthor":""},{"title":"1261MO Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins)","googleId":"SIrJm2zEaAoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41571-6/abstract","googleCitationCount":1,"googleAuthor":"GJ Riely"},{"title":"89Zr-labeled anti-PD-L1 CX-072 PET imaging in human xenograft and syngeneic tumors","googleId":"LCytYZI8LlYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30019-5/abstract","googleCitationCount":4,"googleAuthor":"MN Lub-De Hooge"},{"title":"Immunotherapy for early breast cancer: too soon, too superficial, or just right?","googleId":"sYebn7048YoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420431989","googleCitationCount":0,"googleAuthor":"MA Franzoi"},{"title":"Impact of tucatinib on progression free survival in patients with HER2+ metastatic breast cancer and stable or active brain metastases","googleId":"WOqWRwvqpl8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40391-6/abstract","googleCitationCount":1,"googleAuthor":"NU Lin"},{"title":"ANCHOR CRC: A phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BINI), plus cetuximab (CETUX) in patients with previously …","googleId":"o1HzbkB3jaMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30911-1/abstract","googleCitationCount":7,"googleAuthor":"A Grothey"},{"title":"Efficacy and safety of first China-manufactured trastuzumab biosimilar HLX02 for metastatic breast cancer: A phase III trial","googleId":"EcdVH7h5gNEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585313","googleCitationCount":2,"googleAuthor":""},{"title":"Basal NK activity and early Treg function inhibition predicts Nivolumab responsiveness in metastatic renal cancer patients (REVOLUTION) trial","googleId":"iujQYs4F7JoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419600359","googleCitationCount":2,"googleAuthor":""},{"title":"CN14 The utility of a brief clinical frailty scale (CFS) in predicting prognosis and discharge destination in oncology inpatients","googleId":"2HGbUOJMhjsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42184-2/abstract","googleCitationCount":1,"googleAuthor":""},{"title":"Atezolizumab in combination with bevacizumab for patients with unresectable/metastatic anal cancer","googleId":"stf_1Rbb89sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40510-1/abstract","googleCitationCount":1,"googleAuthor":""},{"title":"Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk …","googleId":"anvSGoPYA_AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591323","googleCitationCount":2,"googleAuthor":"JL Boormans"},{"title":"Integrative analysis of metabolic subtypes in triple-negative breast cancer reveals new therapeutic strategies","googleId":"K2m7GyTjNQYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)57684-0/abstract","googleCitationCount":2,"googleAuthor":""},{"title":"PD-1 Systematic review and meta-analysis of the efficacy of chemotherapeutic regimens in advanced gallbladder cancer: Assessing current practice and …","googleId":"FUMHmJ5sa2EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39756-8/pdf","googleCitationCount":1,"googleAuthor":""},{"title":"First-line versus second-line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck","googleId":"hfJoBMQsxnEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593504","googleCitationCount":2,"googleAuthor":"T Ibrahim"},{"title":"Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck …","googleId":"KypbCAHcyn0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325965","googleCitationCount":6,"googleAuthor":""},{"title":"560P Safety and efficacy of Debio 1143, an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in a phase Ib/II trial in patients (pts) …","googleId":"o5v912RcMqUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40670-2/abstract","googleCitationCount":1,"googleAuthor":"V Moreno"},{"title":"ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre-and post-operative therapy in metastatic renal cell carcinoma","googleId":"jR8UP_IqdjgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591232","googleCitationCount":2,"googleAuthor":"K Litchfield"},{"title":"Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120 mg every 14 days in patients with progressive pancreatic or midgut …","googleId":"VRxsloAi5NcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595977","googleCitationCount":2,"googleAuthor":"P Ruszniewski"},{"title":"833P Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and …","googleId":"O2tHeIifR0IJ","googleLink":"https://www.clearityfoundation.org/wp-content/uploads/2020/10/Mirv-and-CarboPt-and-Bev-ESMO-2020-abstract.pdf","googleCitationCount":1,"googleAuthor":"IB Vergote"},{"title":"633P Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III …","googleId":"uG0jYDN-dI8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40888-9/abstract","googleCitationCount":1,"googleAuthor":""},{"title":"Patient-reported outcomes associated with switching to rivaroxaban for the treatment of venous thromboembolism (VTE) in patients with active cancer","googleId":"1X0gEWAsBXgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419599069","googleCitationCount":2,"googleAuthor":"AT Cohen"},{"title":"CRYODESMO-O1: A French nationwide phase II study on cryoablation in progressing desmoid tumour (DT) patients (pts)","googleId":"qPPV5tYr15IJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419602905","googleCitationCount":2,"googleAuthor":"X Buy"},{"title":"Mutation tracking in circulating tumour DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies …","googleId":"B_LK2dxCXp4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587439","googleCitationCount":2,"googleAuthor":""},{"title":"375O Final efficacy results from IMpower132: First-line atezolizumab+ chemotherapy in patients with stage IV non-squamous NSCLC","googleId":"ARmSy5Aheq4J","googleLink":"https://digitalcommons.psjhealth.org/publications/4179/","googleCitationCount":1,"googleAuthor":""},{"title":"Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer","googleId":"DGUwXDRfcWEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588342","googleCitationCount":2,"googleAuthor":"Y Nakamura"},{"title":"Pharmacokinetic (PK) analysis of weight-based and fixed dose cemiplimab in patients (pts) with advanced malignancies","googleId":"PQUTwvhfc9UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959490X","googleCitationCount":2,"googleAuthor":""},{"title":"1922P Exploratory patient-reported outcomes among patients with RET-mutant medullary thyroid cancer in LIBRETTO-001: A phase I/II trial of selpercatinib (LOXO …","googleId":"IewcorYOaKoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41406-1/abstract","googleCitationCount":1,"googleAuthor":"DSW Tan"},{"title":"1255TiP CheckMate 73L: A phase III study comparing nivolumab (NIVO) plus concurrent chemoradiotherapy (CCRT) followed by NIVO±ipilimumab (IPI) versus CCRT …","googleId":"HzqNwfiVwEoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40124-3/abstract","googleCitationCount":1,"googleAuthor":"D De Ruysscher"},{"title":"735P Metastatic renal medullary and collecting duct carcinoma in the era of antiangiogenic and immune checkpoint inhibitors: A multicentric retrospective study","googleId":"LF5K4uty_74J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40803-8/abstract","googleCitationCount":1,"googleAuthor":""},{"title":"Relationships between approved combination therapies and clinical data packages in anti-cancer drugs in Japan","googleId":"agtxvr933WwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)62115-0/abstract","googleCitationCount":2,"googleAuthor":"S Shibata"},{"title":"1620O Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma","googleId":"QL1UTYzSdDMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41842-3/abstract","googleCitationCount":1,"googleAuthor":""},{"title":"Multicenter phase II trial of axitinib monotherapy for advanced biliary tract cancer refractory to gemcitabine-based chemotherapy","googleId":"4EkgiJdfoA8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589542","googleCitationCount":2,"googleAuthor":""},{"title":"Differential expression of immunoregulatory molecules and highly-associated cancer genes may provide novel insights into strategic trial design for …","googleId":"eGUdGonHd8EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594479","googleCitationCount":2,"googleAuthor":"JJ Adashek"},{"title":"1256TiP Phase III study of pembrolizumab (Pembro) with concurrent chemoradiation therapy (CCRT) followed by pembro with or without olaparib (Ola) vs CCRT …","googleId":"_keJheLVu6QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40147-4/abstract","googleCitationCount":2,"googleAuthor":"T Kato"},{"title":"1914MO Randomized phase II study of radiation therapy and paclitaxel with pazopanib or placebo: NRG-RTOG 0912","googleId":"akhEJ0vvpTcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41398-5/abstract","googleCitationCount":1,"googleAuthor":""},{"title":"LBA48 Clinical efficacy and immunity of combination therapy with nivolumab and IDO/PD-L1 peptide vaccine in patients with metastatic melanoma: A phase I/II trial","googleId":"qgqqPxUMuT8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42360-9/abstract","googleCitationCount":1,"googleAuthor":""},{"title":"810MO Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial","googleId":"PDS1Ci9Si98J","googleLink":"https://www.researchgate.net/profile/Lydia_Gaba2/publication/345369214_810MO_Patient-reported_outcomes_PROs_in_patients_pts_receiving_niraparib_in_the_PRIMAENGOT-OV26GOG-3012_trial/links/5fac2cfe45851507810c6247/810MO-Patient-reported-outcomes-PROs-in-patients-pts-receiving-niraparib-in-the-PRIMA-ENGOT-OV26-GOG-3012-trial.pdf","googleCitationCount":1,"googleAuthor":"F Heitz"},{"title":"Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab (BEV), carboplatin (C) and paclitaxel (P) for advanced cervical …","googleId":"5yMGZYzEQGkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419592663","googleCitationCount":2,"googleAuthor":"N Colombo"},{"title":"LBA1 Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence","googleId":"1gtQRydSW8EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42361-0/abstract","googleCitationCount":1,"googleAuthor":""},{"title":"973TiP LEAP-010: Phase III study of first-line pembrolizumab with or without lenvatinib in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell …","googleId":"UtiKVD5wyxkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41084-1/abstract","googleCitationCount":1,"googleAuthor":"LL Siu"},{"title":"LBA1 Interim results of a phase I/Ib study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib (RIB) or alpelisib (ALP) in …","googleId":"JwdSWsqQNjMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39305-4/abstract","googleCitationCount":4,"googleAuthor":""},{"title":"915MO Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+ C) vs EXTREME (E) as first-line (1L) therapy for …","googleId":"2qUEWpUGcj4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41026-9/abstract","googleCitationCount":1,"googleAuthor":"R Greil"},{"title":"A phase III trial of capivasertib and fulvestrant versus placebo and fulvestrant in patients with HR+/HER2− breast cancer (CAPItello-291)","googleId":"qWpq2Vlgh7wJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40448-X/abstract","googleCitationCount":1,"googleAuthor":"H Gomez"},{"title":"nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2-metastatic breast cancer","googleId":"6gZitA8fgOcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40371-0/abstract","googleCitationCount":2,"googleAuthor":""},{"title":"1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations","googleId":"bhmE0KVSISwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41603-5/abstract","googleCitationCount":2,"googleAuthor":""},{"title":"Safety profile of tepotinib in patients with advanced solid tumors: Pooled analysis of phase I and II data","googleId":"2oDQPhGScwAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587014","googleCitationCount":2,"googleAuthor":""},{"title":"Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia","googleId":"y1RZxKuk894J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311329","googleCitationCount":3,"googleAuthor":"J Yin"},{"title":"SO-3 Maintenance olaparib in patients aged≥ 65 years with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial","googleId":"8Yv2sJvT6dsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39317-0/pdf","googleCitationCount":1,"googleAuthor":"P Hammel"},{"title":"Palbociclib-fulvestrant (PALBO-FUL) and everolimus-exemestane (EVE-EXE) for second line hormonal treatment (HT) of metastatic breast cancer (MBC) with …","googleId":"xD5spR4tj_oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585611","googleCitationCount":2,"googleAuthor":"A Orlandi"},{"title":"A phase Ib/II study of APG-115 in combination with pembrolizumab in patients with unresectable or metastatic melanomas or advanced solid tumors","googleId":"gXfXABWXVs0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30012-2/abstract","googleCitationCount":3,"googleAuthor":""},{"title":"Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: preliminary results","googleId":"6ByIHVIf1kYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30947-0/abstract","googleCitationCount":2,"googleAuthor":""},{"title":"O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or …","googleId":"nVo1n8hbzWQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39364-9/pdf","googleCitationCount":1,"googleAuthor":"M Özgüroğlu"},{"title":"Sarcoidosis-like reaction mimics progression in patients treated with immune checkpoint inhibitors","googleId":"PcMKTU9myeMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595138","googleCitationCount":1,"googleAuthor":"L Dercle"},{"title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.","googleId":"67zBGPfQwbgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420429801","googleCitationCount":0,"googleAuthor":"M Schmitt"},{"title":"The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers","googleId":"StuV43LM6-0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43225-0/abstract","googleCitationCount":1,"googleAuthor":"JC Soria"},{"title":"Drinking alcohol, smoking, multiple dysplastic lesions and the risk of field cancerization of squamous cell carcinoma in the esophagus and head and neck …","googleId":"8vgKZGg1stkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589815","googleCitationCount":2,"googleAuthor":""},{"title":"T-cell bispecific antibodies to bypass MHC class I loss in breast cancer","googleId":"lUXD5Q8uKuoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31207-4/abstract","googleCitationCount":2,"googleAuthor":"A Marra"},{"title":"Risk and impact of renal impairment of locally advanced head and neck squamous cell carcinoma patients who received chemoradiotherapy with cisplatin","googleId":"671672nGWlgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593449","googleCitationCount":2,"googleAuthor":""},{"title":"cfDNA analysis from phase I/II study of lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2-advanced breast cancer patients","googleId":"oy-99SWGxfYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40376-X/abstract","googleCitationCount":1,"googleAuthor":""},{"title":"Trifluridine/tipiracil in metastatic colorectal cancer: An updated multicentre real-world analysis on efficacy, safety and predictive factors","googleId":"9feVajlwTO0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588202","googleCitationCount":1,"googleAuthor":"C Stavraka"},{"title":"LBA-7 Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic …","googleId":"wKjH-Apta5MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39901-4/pdf","googleCitationCount":1,"googleAuthor":"A Grothey"},{"title":"1986P MDM2 amplification and hyperprogression following treatment with immune checkpoint inhibitors in advanced non-small cell lung cancer","googleId":"65ykF2K6ZpgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41288-8/abstract","googleCitationCount":2,"googleAuthor":""},{"title":"Expression of PD-L1 in plasma exosomes of NSCLC patients and its associations with PD-L1 expression of corresponding tumour tissues","googleId":"I5ScCeYtBR4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)58369-7/abstract","googleCitationCount":2,"googleAuthor":""},{"title":"Calcium and vitamin D intake and colorectal cancer morbidity rates in Poland","googleId":"gINSqbrPimcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30702-1/abstract","googleCitationCount":2,"googleAuthor":""},{"title":"A comprehensive model of genetic-features predicts outcome of personalized adjuvant treatment in resected EGFR-mutant stage II-IIIA NSCLC: Results from a …","googleId":"5hFkV9SdP4YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596508","googleCitationCount":2,"googleAuthor":""},{"title":"Inactivation of RB1 and histological transformation in EGFR-mutant lung adenocarcinoma","googleId":"xer-T65hrJkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)53227-6/abstract","googleCitationCount":1,"googleAuthor":"M Jamal-Hanjani"},{"title":"Personal antigen selection calculator (PASCal) for the design of personal cancer vaccines","googleId":"94ZhRiFcsI4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593930","googleCitationCount":2,"googleAuthor":""},{"title":"Comprehensive genomic and transcriptomic profiling in advanced-stage cancers and rare malignancies: Clinical results from the MASTER trial of the German …","googleId":"VBqsrTnuLJ4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419619794","googleCitationCount":1,"googleAuthor":""},{"title":"Patients should be the tipping point of individualizing breast cancer surgery: Commentary on 'Eliminating the breast cancer surgery paradigm after neoadjuvant …","googleId":"ULCB3jPL9iUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39844-6/fulltext","googleCitationCount":1,"googleAuthor":""},{"title":"Trilaciclib improves overall survival when given with gemcitabine/carboplatin (GC) in patients with metastatic triple negative breast cancer (mTNBC) in a …","googleId":"sFkFRBwmHaoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603716","googleCitationCount":1,"googleAuthor":""},{"title":"Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced …","googleId":"O_JR-p5pnmsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30743-4/abstract","googleCitationCount":2,"googleAuthor":"I Borbath"},{"title":"Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic …","googleId":"gcnNZ0WMpM4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419578036","googleCitationCount":1,"googleAuthor":"P Hammel"},{"title":"SO-5 Efficacy of second-line chemotherapy in patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions: A retrospective analysis","googleId":"Z_pafHY7GMAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39319-4/pdf","googleCitationCount":1,"googleAuthor":"S Roychowdhury"},{"title":"Sequential treatment with afatinib followed by 3rd generation EGFR-TKI–subgroup analysis of the GIDEON trial: A prospective non-interventional study (NIS) …","googleId":"3RFqdhqFUsIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597344","googleCitationCount":1,"googleAuthor":""},{"title":"Clinical benefit and prices of cancer drugs in the US and Europe","googleId":"BFvgEUdXwJ0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604461","googleCitationCount":1,"googleAuthor":"TJ Rosemann"},{"title":"EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in non-small-cell lung cancer","googleId":"sVclRPc67_4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31295-5/abstract","googleCitationCount":3,"googleAuthor":"S Peters"},{"title":"THOR-707, a novel not-alpha IL-2, promotes all key immune system anti-tumoral actions of IL-2 without eliciting vascular leak syndrome (VLS)","googleId":"TgobxYTR3YIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594376","googleCitationCount":1,"googleAuthor":""},{"title":"Treatment compliance in early-stage anal cancer","googleId":"NqMJpWbtFlgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39941-5/abstract","googleCitationCount":1,"googleAuthor":""},{"title":"ESMO-MCBS and health technology assessment (HTA): Does value for physicians correspond to value for payers?","googleId":"spiEMXlmivYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419598325","googleCitationCount":2,"googleAuthor":""},{"title":"3O Mutation analysis of circulating tumour DNA from baseline and study discontinuation samples in SANDPIPER, a phase III study of taselisib or placebo with …","googleId":"OUd4oL6qsqwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36218-9/abstract","googleCitationCount":1,"googleAuthor":""},{"title":"Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer","googleId":"gKnxvFJ3ChQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40456-9/abstract","googleCitationCount":1,"googleAuthor":""},{"title":"Efficacy and safety of early administration of pegfilgrastim in patients with esophageal cancer treated by docetaxel, cisplatin, and 5-fluorouracil (DCF): a phase 2 …","googleId":"Mt2DvbCYFfcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30576-9/abstract","googleCitationCount":2,"googleAuthor":""},{"title":"Does adjuvant therapy reduce postmetastatic survival?","googleId":"-IWTwYUh7uAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31279-7/abstract","googleCitationCount":4,"googleAuthor":""},{"title":"KEYNOTE-495/KeyImPaCT: A randomized, biomarker-directed, phase II trial of pembrolizumab-based therapy for non–small cell lung cancer (NSCLC)","googleId":"vPES9qw9-ewJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597964","googleCitationCount":1,"googleAuthor":"M Gutierrez"},{"title":"Safety and antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors: Ovarian cancer cohort data","googleId":"VyWm6T5VmXIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344811","googleCitationCount":1,"googleAuthor":"J Goh"},{"title":"1686P The impact of the COVID-19 crisis on perceived changes in care and wellbeing of cancer patients and norm participants: Results of the PROFILES registry","googleId":"We0CRr7hCNMJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506350/","googleCitationCount":1,"googleAuthor":"LV Van de Poll-Franse"},{"title":"CAM-H2 effectively targets and treats HER2 positive brain lesions: A comparative preclinical study with trastuzumab","googleId":"lqrcfCD8X58J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30452-1/abstract","googleCitationCount":2,"googleAuthor":"M D'Huyvetter"},{"title":"1761P Universal screening of SARS-CoV-2 of oncology healthcare workers—a Brazilian experience","googleId":"Pqbx6qaEleoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41821-6/abstract","googleCitationCount":1,"googleAuthor":""},{"title":"Natural dendritic cell vaccinations generate immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate …","googleId":"MqsjJTjPqzgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593917","googleCitationCount":1,"googleAuthor":""},{"title":"SYNERGY: Phase I and randomized phase II trial to investigate the addition of the anti-CD73 antibody oleclumab to durvalumab, paclitaxel and carboplatin for …","googleId":"RcE-NvuOiXAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30463-6/abstract","googleCitationCount":2,"googleAuthor":"D Eiger"},{"title":"CN5 Video consultations with older patients in the oncology nursing outpatient clinic","googleId":"-_HRuKob9zEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42173-8/abstract","googleCitationCount":1,"googleAuthor":"KB Dieperink"},{"title":"Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine","googleId":"E6PI733lPH4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420431680","googleCitationCount":0,"googleAuthor":"G Malleo"},{"title":"Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: Association with toxicity and treatment outcome","googleId":"9jN25C6C5q4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591852","googleCitationCount":1,"googleAuthor":"A Desnoyer"},{"title":"Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non …","googleId":"BM80VvjOZvMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419581522","googleCitationCount":1,"googleAuthor":""},{"title":"Adverse event (AE) kinetics in patients (pts) treated with dabrafenib+ trametinib (D+ T) in the metastatic and adjuvant setting","googleId":"RD4eizhxe4QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595436","googleCitationCount":1,"googleAuthor":"VG Atkinson"},{"title":"Lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed continuously in combination with osimertinib for EGFRmut non-small cell lung cancer: Initial phase Ib …","googleId":"J3gfDnPW7BAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597447","googleCitationCount":1,"googleAuthor":""},{"title":"First China-manufactured trastuzumab biosimilar HLX02 global phase III trial met primary endpoint in breast cancer","googleId":"P2gG6v2AKr8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582102","googleCitationCount":1,"googleAuthor":""},{"title":"Pioglitazone and clarithromycin combined with metronomic low-dose chemotherapy versus nivolumab in patients with advanced non-small cell lung cancer …","googleId":"jLzf3Z5Def8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597770","googleCitationCount":1,"googleAuthor":""},{"title":"Induction gefitinib followed by standard chemoradiotherapy in locally advanced (LA) non-small cell lung cancer (NSCLC) with epidermal growth factor …","googleId":"6MqQ3ixX2c4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419581200","googleCitationCount":1,"googleAuthor":""},{"title":"ACTL6A is a novel oncogene and prognostic biomarker for prostate cancer","googleId":"7iOypAmsw7kJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)62164-2/abstract","googleCitationCount":2,"googleAuthor":""},{"title":"Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors","googleId":"E_MOggVKGL0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344483","googleCitationCount":1,"googleAuthor":""},{"title":"CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC)","googleId":"0RzqGui7u6oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604047","googleCitationCount":1,"googleAuthor":""},{"title":"ADRIATIC: A phase III trial of durvalumab±tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer","googleId":"ftbI-B4GBZQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30216-9/abstract","googleCitationCount":4,"googleAuthor":""},{"title":"KEYLYNK-010: Phase III study of pembrolizumab (pembro) plus olaparib (OLA) vs enzalutamide (ENZA) or abiraterone (ABI) in ENZA-or ABI-pretreated …","googleId":"hT32St6t38oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591098","googleCitationCount":1,"googleAuthor":"E Yu"},{"title":"O-16 Relative impact of T4 and N2 on the efficacy of 3 versus 6 months of adjuvant CAPOX for high-risk stage II and stage III colon cancer: ACHIEVE and …","googleId":"OdXen-7HWm0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39368-6/pdf","googleCitationCount":1,"googleAuthor":""},{"title":"FGFR2 fusions and its effect of patient (pt) outcomes in intrahepatic cholangiocarcinoma (iCCA)","googleId":"k2CcsSvkTxsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589438","googleCitationCount":2,"googleAuthor":""},{"title":"FOLFOXIRI versus FOLFOX or FOLFIRI with targeted therapy in patients with mutant BRAF metastatic colorectal cancer: A systematic review and meta-analysis","googleId":"lHaRMqGuDzYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40573-3/abstract","googleCitationCount":3,"googleAuthor":""},{"title":"Relation between objective tumour shrinkage and progression-free survival (PFS) in the NETTER-1 population","googleId":"xP4E40xlVZoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595916","googleCitationCount":1,"googleAuthor":"P Broberg"},{"title":"Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR-T therapy in metastatic colorectal cancer","googleId":"Td_fJZvc2JIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30953-6/abstract","googleCitationCount":3,"googleAuthor":"J Machiels"},{"title":"Understanding mechanisms of primary resistance to checkpoint inhibitors will lead to precision immunotherapy of advanced gastric cancer","googleId":"gKFnfrSlMbwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31088-9/abstract","googleCitationCount":2,"googleAuthor":"A Cervantes"},{"title":"Next-generation sequencing (NGS) in metastatic colorectal cancer (mCRC): Novel mutated genes and their effect on response to therapy (Alliance)","googleId":"AkWYnOyFirgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587452","googleCitationCount":1,"googleAuthor":"F Innocenti"},{"title":"Impact of neurological symptom burden on the survival prognosis in a real-life cohort of patients with non-small cell lung cancer brain metastases","googleId":"RTVHl4jhvUAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586240","googleCitationCount":1,"googleAuthor":""},{"title":"Combined detection of CD137 and type 1 functions improves identification and characterization of the activated T lymphocyte repertoire","googleId":"oF5sYcgRVlIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344689","googleCitationCount":1,"googleAuthor":"A Draghi"},{"title":"Addition of an oral docetaxel treatment (ModraDoc006/r) to androgen deprivation therapy (ADT) and intensity-modulated radiation therapy (IMRT) in patients …","googleId":"fERiGY0xi8cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591153","googleCitationCount":1,"googleAuthor":"JM Janssen"},{"title":"PIPAC paclitaxel: A systematic and peritoneal tissue pharmacokinetic study in swine","googleId":"9RGf8S4QxvwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30787-2/abstract","googleCitationCount":2,"googleAuthor":"G Kim"},{"title":"Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients","googleId":"LDeNl8LgkvcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594534","googleCitationCount":2,"googleAuthor":"R Laza-Briviesca"},{"title":"Efficacy of weekly paclitaxel-bevacizumab combination in advanced non squamous non-small cell lung cancer (NSCLC) progressing after immune checkpoint …","googleId":"43nEeF8SvQUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344598","googleCitationCount":2,"googleAuthor":""},{"title":"St Gallen International Consensus Guidelines in early breast cancer: experts to prevent patients' overtreatment and breaking the bank?","googleId":"fkRqMy5pLNsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)60985-3/abstract","googleCitationCount":1,"googleAuthor":""},{"title":"Chemotherapy-free treatments: are we ready for prime time?","googleId":"j5UHrrShDjkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31135-4/abstract","googleCitationCount":2,"googleAuthor":""},{"title":"Interim results from trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumours","googleId":"jkuMuSTAGRkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586884","googleCitationCount":1,"googleAuthor":""},{"title":"Future of checkpoint blockade in triple-negative breast cancer: combination strategies to lead the way","googleId":"MvqWZxdZgv8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31094-4/abstract","googleCitationCount":2,"googleAuthor":""},{"title":"Extracellular matrix and tissue derived metabolites in a liquid biopsy identifies endotypes of metastatic melanoma patients with differential response to …","googleId":"oLMHQTDc_GoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594613","googleCitationCount":1,"googleAuthor":"N Willumsen"},{"title":"Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) versus best supportive care (BSC) in previously systemically treated patients (pts) …","googleId":"jXFA4DdbIloJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588950","googleCitationCount":1,"googleAuthor":""},{"title":"A phase Ib study of the safety and efficacy of atezolizumab (atezo)+ bevacizumab (bev)+ cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer …","googleId":"TD278wIMCsYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588238","googleCitationCount":1,"googleAuthor":"C Lieu"},{"title":"Predictive value of neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) In hepatocellular carcinoma (HCC) patients treated with nivolumab …","googleId":"I07qd83MzwcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341958961X","googleCitationCount":4,"googleAuthor":"S Dharmapuri"},{"title":"Combination of triptorelin with nivolumab in ICI resistant advanced melanoma","googleId":"vbogscWIyFAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420345063","googleCitationCount":1,"googleAuthor":""},{"title":"SO-20 Consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer (mCRC): Prognostic and predictive impact in the …","googleId":"gvMOfy8USTMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39334-0/pdf","googleCitationCount":1,"googleAuthor":"E Fontana"},{"title":"From astrology to prostate cancer: what is the role of subgroup analyses?","googleId":"kZfkia4YjDEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)40700-X/abstract","googleCitationCount":1,"googleAuthor":"C Cattrini"},{"title":"1061P TCR and HLA analysis of patients in a phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM)","googleId":"t-v6NdueLaIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41177-9/abstract","googleCitationCount":1,"googleAuthor":"DE Anderson"},{"title":"Real-world implementation of sequential targeted therapies for EGFR-mutated NSCLC","googleId":"X6PzddP8yL8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597459","googleCitationCount":1,"googleAuthor":"AL Volckmar"},{"title":"Patient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen …","googleId":"wdypMvur_2EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590676","googleCitationCount":1,"googleAuthor":"N Agarwal"},{"title":"Splenic metabolic activity as biomarker in cervical cancer","googleId":"RsgPRl1WWwAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419583818","googleCitationCount":1,"googleAuthor":"EA De Jaeghere"},{"title":"Expression analysis of NHEJ and HR genes in Ewing sarcomas: Indications of DSB repair dysfunction","googleId":"GNJMS0UWq2MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603480","googleCitationCount":1,"googleAuthor":"M Liontos"},{"title":"Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)","googleId":"BybQbBQefOwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591438","googleCitationCount":1,"googleAuthor":""},{"title":"ADP-A2M4 (MAGE-A4) in patients with synovial sarcoma","googleId":"ifUK-TOgwHoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419602929","googleCitationCount":4,"googleAuthor":"BA Van Tine"},{"title":"Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis","googleId":"Vhb10xmGYcUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419577006","googleCitationCount":1,"googleAuthor":"A Shamshirian"},{"title":"First in human phase I/IIa study of PEN-866, a heat shock protein 90 (HSP90) ligand–SN38 conjugate for patients with advanced solid tumours: Phase I …","googleId":"6yOJo9dSgCEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586835","googleCitationCount":1,"googleAuthor":""},{"title":"1880P Two thousand consecutive parallel evaluations of Karnofsky and ECOG performance status: looking for a correct comparison","googleId":"QLEyvLxmvE8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41523-6/abstract","googleCitationCount":1,"googleAuthor":""},{"title":"The extended/phase II study of safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate resistant prostate cancer (mCRPC) who …","googleId":"xjRTrUh-71QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591141","googleCitationCount":1,"googleAuthor":""},{"title":"Radiosurgery followed by tumour treating fields (TTFields) for brain metastases (1-10) from NSCLC in the phase III METIS trial","googleId":"7Y5XXzKdM14J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419598015","googleCitationCount":1,"googleAuthor":""},{"title":"Ribociclib (RIB)+ letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) …","googleId":"yze9x7dnfdQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585556","googleCitationCount":1,"googleAuthor":""},{"title":"The extended/phase II study of safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate resistant prostate cancer (mCRPC) who …","googleId":"xjRTrUh-71QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591141","googleCitationCount":1,"googleAuthor":""},{"title":"Radiosurgery followed by tumour treating fields (TTFields) for brain metastases (1-10) from NSCLC in the phase III METIS trial","googleId":"7Y5XXzKdM14J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419598015","googleCitationCount":1,"googleAuthor":""},{"title":"Ribociclib (RIB)+ letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) …","googleId":"yze9x7dnfdQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585556","googleCitationCount":1,"googleAuthor":"PH Cottu"},{"title":"Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma","googleId":"cpej2ItxAR4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603091","googleCitationCount":1,"googleAuthor":""},{"title":"A Phase I Study of an Anti-IDO1 Inhibitor (LY3381916) as Monotherapy and in Combination with an Anti-PD-L1 Antibody (LY3300054) in Patients with …","googleId":"wBU_3ms3b4EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344999","googleCitationCount":1,"googleAuthor":"B O'Neil"},{"title":"ACCURACY a phase (P) II trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch …","googleId":"HHkW1RRqr7UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593607","googleCitationCount":2,"googleAuthor":""},{"title":"SO-007Regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer: an open-label, dose-finding, and dose-expansion phase 1b trial …","googleId":"qpidwajojO4J","googleLink":"https://lirias.kuleuven.be/retrieve/569297","googleCitationCount":3,"googleAuthor":""},{"title":"Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor","googleId":"9QCOzUf91I0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420431709","googleCitationCount":3,"googleAuthor":""},{"title":"126TiP a Phase I Study of NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy","googleId":"vg0QQo3BGZAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420345129","googleCitationCount":1,"googleAuthor":""},{"title":"A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated …","googleId":"G-mO4Q6gxDQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30466-1/abstract","googleCitationCount":2,"googleAuthor":"E Paplomata"},{"title":"1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the …","googleId":"72zpEF70Ye8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41924-6/abstract","googleCitationCount":1,"googleAuthor":""},{"title":"Effect of selumetinib plus AZD8186 treatment on cabazitaxel sensitivity in docetaxel-acquired resistant metastatic prostate cancer cell lines","googleId":"vGPUlqLq_gMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419600785","googleCitationCount":1,"googleAuthor":""},{"title":"Aberrant glycolysis associates with inflammatory tumour microenvironment and promotes metastasis in triple negative breast cancer","googleId":"e6Gfl-QLeVsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)58253-9/abstract","googleCitationCount":2,"googleAuthor":""},{"title":"A randomized trial of sodium alginate prevention of radiation-induced esophagitis in patients with locally advanced NSCLC receiving concurrent …","googleId":"qeo4Sm3QL9UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419599380","googleCitationCount":1,"googleAuthor":"I Oze"},{"title":"The impact of late-line treatment on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer …","googleId":"Go4zileQcCYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341958807X","googleCitationCount":1,"googleAuthor":""},{"title":"Prognostic and predictive impact on FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer","googleId":"9j71E1XhOI4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588561","googleCitationCount":1,"googleAuthor":""},{"title":"Pertuzumab (P)+ trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer …","googleId":"Io66kfPm7iMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30418-1/abstract","googleCitationCount":2,"googleAuthor":""},{"title":"Application of multi-modal approach to palliation in end of life head and neck cancer pain","googleId":"yau8u-8CYDUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341958005X","googleCitationCount":1,"googleAuthor":""},{"title":"Applicability of the LIPI score to metastatic microsatellite instability high cancer patients treated with immune checkpoint inhibitors","googleId":"_eq8q8qZ_QcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344331","googleCitationCount":1,"googleAuthor":""},{"title":"Platelet Lymphocyte Ratio (PLR) Related with Clinicopathological Characteristics of Balinese Women Breast Cancer Patient","googleId":"cmSZPWL1sAkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419623732","googleCitationCount":4,"googleAuthor":""}]